10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended April 30, 2021.

or

☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-55863

RAFAEL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	82-2296593
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

520 Broad Street, Newark, New Jersey 07102

(Address of principal executive offices, zip code)

(212) 658-1450

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class B common stock, par value $0.01 per share	RFL	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐   No ☒

The number of shares outstanding of the registrant’s common stock as of June 14, 2021 was:

Class A common stock, par value $0.01 per share:	787,163 shares
Class B common stock, par value $0.01 per share:	16,927,318 shares

RAFAEL HOLDINGS, INC.

TABLE OF CONTENTS

Part I. FINANCIAL INFORMATION
	Item 1.	Financial Statements (Unaudited)	1
		Consolidated Balance Sheets as of April 30, 2021 and July 31, 2020	1
		Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended April 30, 2021 and 2020	2
		Consolidated Statements of Equity for the Three and Nine Months Ended April 30, 2021 and 2020	3
		Consolidated Statements of Cash Flows for the Nine Months Ended April 30, 2021 and 2020	5
		Notes to Consolidated Financial Statements	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
	Item 3.	Quantitative and Qualitative Disclosures about Market Risks	30
	Item 4.	Controls and Procedures	30
Part II. OTHER INFORMATION
	Item 1.	Legal Proceedings	31
	Item 1A.	Risk Factors	31
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
	Item 3.	Defaults Upon Senior Securities	31
	Item 4.	Mine Safety Disclosures	31
	Item 5.	Other Information	31
	Item 6.	Exhibits	32
SIGNATURES			33

i

PART 1. FINANCIAL INFORMATION

ITEM 1. Financial Statements

RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

	April 30, 2021 (unaudited)			July 31, 2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	4,679		$	6,206
Trade accounts receivable, net of allowance for doubtful accounts of $183 and $218 at April 30, 2021 and July 31, 2020, respectively		248			267
Due from Rafael Pharmaceuticals		480			118
Prepaid expenses and other current assets		625			273
Assets held for sale		—			2,968
Total current assets		6,032			9,832
Property and equipment, net		43,591			44,433
Equity investment – RP Finance LLC		479			192
Due from RP Finance LLC		3,750			—
Investments – Rafael Pharmaceuticals		79,141			70,018
Investments – Other Pharmaceuticals		477			1,201
Investments – Hedge Funds		9,681			7,510
Deferred income tax assets, net		—			6
In-process research and development and patents		1,575			1,575
Other assets		1,482			1,580
TOTAL ASSETS	$	146,208		$	136,347
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Trade accounts payable	$	753		$	921
Accrued expenses		861			1,191
Amount due for purchase of membership interest		3,000			3,500
Other current liabilities		235			115
Due to related parties		60			—
Total current liabilities		4,909			5,727
Deferred income tax liabilities, net		9			—
Other liabilities		33			92
TOTAL LIABILITIES		4,951			5,819
COMMITMENTS AND CONTINGENCIES
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2021 and July 31, 2020, respectively		8			8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 15,969,962 issued and 15,982,349 outstanding as of April 30, 2021, and 15,034,598 issued and 15,028,536 outstanding as of July 31, 2020		158			149
Additional paid-in capital		151,258			129,136
Accumulated deficit		(28,419	)		(16,255	)
Accumulated other comprehensive income related to foreign currency translation adjustment		3,766			3,762
Total equity attributable to Rafael Holdings, Inc.		126,771			116,800
Noncontrolling interests		14,486			13,728
TOTAL EQUITY		141,257			130,528
TOTAL LIABILITIES AND EQUITY	$	146,208		$	136,347

1

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited, in thousands, except share and per share data)

	Three Months Ended April 30,						Nine Months Ended April 30,
	2021			2020			2021			2020
REVENUE
Rental - Third Party	$	228		$	360		$	654		$	1,076
Rental - Related Party		523			523			1,570			1,570
Parking		119			221			418			664
Other - Related Party		120			120			360			360
Total revenue		990			1,224			3,002			3,670
COSTS AND EXPENSES
Selling, general and administrative		3,006			2,081			8,365			6,343
Research and development		1,262			634			3,345			1,327
Depreciation and amortization		201			474			1,079			1,413
Impairment - Altira		—			—			7,000			—
Loss from operations		(3,479	)		(1,965	)		(16,787	)		(5,413	)
Interest expense, net		(1	)		—			(2	)		(31	)
Net loss resulting from foreign exchange transactions		—			—			—			(5	)
Gain on sale of building		—			—			749			—
Impairment of investments - Other Pharmaceuticals		—			(295	)		(724	)		(295	)
Unrealized gain (loss) on investments - Hedge Funds		738			(28	)		4,171			492
Loss before income taxes		(2,742	)		(2,288	)		(12,593	)		(5,252	)
Provision for income taxes		(4	)		(8	)		(13	)		(24	)
Equity in earnings of RP Finance		96			53			288			53
Consolidated net loss		(2,650	)		(2,243	)		(12,318	)		(5,223	)
Net loss attributable to noncontrolling interests		(97	)		(84	)		(154	)		(213	)
Net loss attributable to Rafael Holdings, Inc.	$	(2,553	)	$	(2,159	)	$	(12,164	)	$	(5,010	)
OTHER COMPREHENSIVE LOSS
Net loss	$	(2,650	)	$	(2,243	)	$	(12,318	)	$	(5,223	)
Foreign currency translation adjustment		5			(4	)		4			(32	)
Total comprehensive loss		(2,645	)		(2,247	)		(12,314	)		(5,255	)
Comprehensive loss attributable to noncontrolling interests		(28	)		(3	)		(39	)		(19	)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$	(2,617	)	$	(2,244	)	$	(12,275	)	$	(5,236	)
Loss per share
Basic and diluted	$	(0.15	)	$	(0.14	)	$	(0.75	)	$	(0.32	)
Weighted average number of shares used in calculation of loss per share
Basic and diluted		16,668,624			15,813,679			16,216,969			15,747,709

2

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(unaudited, in thousands, except share and per share data)

	Three Months Ended April 30, 2021
	Common Stock, Series A				Common Stock, Series B					Additional Paid-in			Accumulated			Accumulated other comprehensive		Noncontrolling			Total
	Shares		Amount		Shares			Amount		Capital			Deficit			income		interests			Equity
Balance at January 31, 2021		787,163	$	8		15,652,120		$	155	$	142,746		$	(25,866	)	$	3,761	$	14,583		$	135,387
Net loss		—		—		—			—		—			(2,553	)		—		(97	)		(2,650	)
Stock-based compensation		—		—		—			—		304			—			—		—			304
Shares issued - Investment in Altira		—		—		231,464			2		6,248			—			—		—			6,250
Shares withheld for payroll taxes		—		—		(920	)		—		(39	)		—			—		—			(39	)
Warrants exercised		—		—		87,298			1		1,999			—			—		—			2,000
Foreign currency translation adjustment		—		—		—			—		—			—			5		—			5
Balance at April 30, 2021		787,163	$	8		15,969,962		$	158	$	151,258		$	(28,419	)	$	3,766	$	14,486		$	141,257

	Nine Months Ended April 30, 2021
	Common Stock, Series A				Common Stock, Series B					Additional Paid-in			Accumulated			Accumulated other comprehensive		Noncontrolling			Total
	Shares		Amount		Shares			Amount		Capital			Deficit			income		interests			Equity
Balance at July 31, 2020		787,163	$	8		15,028,536		$	149	$	129,136		$	(16,255	)	$	3,762	$	13,728		$	130,528
Net loss		—		—		—			—		—			(12,164	)		—		(154	)		(12,318	)
Stock-based compensation		—		—		41,082			—		737			—			—		—			737
Stock-based compensation to Board of Directors		—		—		12,609			—		286			—			—		—			286
Shares issued - Securities Purchase Agreements		—		—		567,437			6		12,994			—			—		—			13,000
Shares issued - Investment in Altira		—		—		231,464			2		6,248			—			—		—			6,250
Shares withheld for payroll taxes		—		—		(7,214	)		—		(185	)		—			—		—			(185	)
Warrants exercised		—		—		87,298			1		1,999			—			—		—			2,000
Stock options exercised		—		—		8,750			—		43			—			—		—			43
Capital contribution for noncontrolling interest		—		—		—			—		—			—			—		912			912
Foreign currency translation adjustment		—		—		—			—		—			—			4		—			4
Balance at April 30, 2021		787,163	$	8		15,969,962		$	158	$	151,258		$	(28,419	)	$	3,766	$	14,486		$	141,257

3

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(unaudited, in thousands, except share and per share data)

	Three Months Ended April 30, 2020
	Common Stock, Series A				Common Stock, Series B					Additional Paid-in			Accumulated			Accumulated other comprehensive			Noncontrolling			Total
	Shares		Amount		Shares			Amount		Capital			Deficit			income			interests			Equity
Balance at January 31, 2020		787,163	$	8		15,020,485		$	149	$	128,843		$	(8,691	)	$	3,756		$	13,854		$	137,919
Net loss		—		—		—			—		—			(2,159	)		—			(84	)		(2,243	)
Stock-based compensation		—		—		3,208			—		135			—			—			—			135
Stock options exercised		—		—		6,000			—		29			—			—			—			29
Shares withheld for payroll taxes		—		—		(824	)		—		(9	)		—			—			—			(9	)
Foreign currency translation adjustment		—		—		—			—		—			—			(4	)		—			(4	)
Balance at April 30, 2020		787,163	$	8		15,028,869		$	149	$	128,998		$	(10,850	)	$	3,752		$	13,770		$	135,827

	Nine Months Ended April 30, 2020
	Common Stock, Series A				Common Stock, Series B					Additional Paid-in			Accumulated			Accumulated other comprehensive			Noncontrolling			Total
	Shares		Amount		Shares			Amount		Capital			Deficit			income			interests			Equity
Balance at July 31, 2019		787,163	$	8		13,142,502		$	131	$	112,898		$	(5,840	)	$	3,784		$	13,783		$	124,764
Net loss		—		—		—			—		—			(5,010	)		—			(213	)		(5,223	)
Stock-based compensation		—		—		24,071			—		338			—			—			—			338
Stock-based compensation to Board of Directors		—		—		12,609			—		208			—			—			—			208
Shares issued for convertible debt		—		—		1,849,749			18		15,650			—			—			—			15,668
Shares withheld for payroll taxes		—		—		(6,062	)		—		(125	)		—			—			—			(125	)
Stock options exercised		—		—		6,000			—		29			—			—			—			29
Conversion of LipoMedix bridge notes		—		—		—			—		—			—			—			200			200
Foreign currency translation adjustment		—		—		—			—		—			—			(32	)		—			(32	)
Balance at April 30, 2020		787,163	$	8		15,028,869		$	149	$	128,998		$	(10,850	)	$	3,752		$	13,770		$	135,827

4

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)

	Nine Months Ended April 30,
	2021			2020
Operating activities
Net loss	$	(12,318	)	$	(5,223	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		1,079			1,413
Deferred income taxes		15			13
Net unrealized gain on investments - Hedge Funds		(4,171	)		(492	)
Impairment of investments - Other Pharmaceuticals		724			295
Impairment - Altira		7,000			—
Equity in earnings of RP Finance		(288	)		(53	)
(Recovery of) provision for doubtful accounts		(183	)		48
Stock-based compensation		1,023			546
Amortization of debt discount		—			54
Gain on sale of building		(749	)		—
Change in assets and liabilities:
Trade accounts receivable		202			141
Prepaid expenses and other current assets		(352	)		171
Other assets		98			(72	)
Accounts payable and accrued expenses		(459	)		28
Other current liabilities		120			—
Due to related parties		60			107
Due from Rafael Pharmaceuticals		(362	)		—
Accrued interest - related party		—			19
Other liabilities		(59	)		30
Net cash used in operating activities		(8,620	)		(2,975	)
Investing activities
Investment in Altira		(1,250	)		—
Purchases of property and equipment		(237	)		(491	)
Payments to fund RP Finance		(3,750	)		—
Proceeds from sale of building		3,658			—
Proceeds related to distribution from Hedge Funds		2,000			—
Investment in Rafael Pharmaceuticals		(9,123	)		—
Net cash used in investing activities		(8,702	)		(491	)
Financing activities
Contribution from noncontrolling interest of consolidated entity		912			—
Proceeds from exercise of options		43			29
Proceeds from exercise of warrants		2,000			—
Proceeds from issuance of shares		13,000			—
Payments for taxes related to shares withheld for employee taxes		(185	)		(125	)
Net cash provided by (used in) financing activities		15,770			(96	)
Effect of exchange rate changes on cash and cash equivalents		25			(32	)
Net decrease in cash and cash equivalents		(1,527	)		(3,594	)
Cash and cash equivalents, beginning of period		6,206			12,024
Cash and cash equivalents, end of period	$	4,679		$	8,430
Supplemental schedule of noncash investing and financing activities
Common shares issued for payment of purchase price for Altira equity	$	6,250		$	—
Conversion of LipoMedix bridge notes	$	—		$	200
Conversions of related party convertible notes payable and accrued interest	$	—		$	15,668

5

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 – DESCRIPTION OF BUSINESS

Rafael Holdings, Inc. (“Rafael Holdings” or the “Company”), a Delaware corporation, owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business.

The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells; and, a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, the Company established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions. In addition, the Company has recently initiated efforts to develop other early stage pharmaceutical ventures including Levco Pharmaceuticals Ltd. (“Levco”), an Israeli company, established to partner with Dr. Alberto Gabizon and a top institution in Israel on the development of novel compounds for cancer, and Farber Partners, LLC (“Farber”), formed around an agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program. Additionally, in 2021, the Company established Rafael Medical Devices, LLC (“Rafael Medical Devices”), a wholly-owned orthopedic device company developing instruments and implants to advance minimally invasive surgeries in the upper and lower extremities.

The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain other entities and hosts other tenants and an associated 800-car public garage, and a portion of a building in Israel. In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

The “Company” in these consolidated financial statements refers to Rafael Holdings on a consolidated basis. All significant intercompany accounts and transactions have been eliminated in consolidation.

All majority-owned subsidiaries are consolidated with all intercompany transactions and balances eliminated in consolidation or combination. The entities included in these consolidated financial statements are as follows:

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware	100	%
Broad Atlantic Associates, LLC	United States – Delaware	100	%
IDT 225 Old NB Road, LLC	United States – Delaware	100	%
IDT R.E. Holdings Ltd.	Israel	100	%
Rafael Holdings Realty, Inc.	United States – Delaware	100	%
Barer Institute, Inc.	United States – Delaware	100	%
The Barer Institute, LLC	United States – Delaware	100	%
Hillview Avenue Realty, JV	United States – Delaware	100	%
Hillview Avenue Realty, LLC	United States – Delaware	100	%
Rafael Medical Devices, LLC	United States – Delaware	100	%
Levco Pharmaceuticals Ltd.	Israel	95	%
Farber Partners, LLC	United States – Delaware	93	%
Pharma Holdings, LLC	United States – Delaware	90	%
LipoMedix Pharmaceuticals Ltd.	Israel	68	%
Altira Capital & Consulting, LLC	United States – Delaware	67	%
CS Pharma Holdings, LLC	United States – Delaware	45	%*

* 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

6

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020).

Operating results for the three and nine months ended April 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (the “SEC”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.

Liquidity

Management believes that its cash on hand, planned forecast, and expected ability to meet its obligations alleviates the substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of the issuance of these financial statements. The Company has no outstanding long term debt due within 12 months and has cash reserves which will enable it to meet obligations for over a year, without attempt to monetize assets via increasing building occupancy or selling assets. The Company can liquidate its investments in hedge funds to generate cash if needed, and the Company could consider alternative sources of funding if necessary.

Risks and Uncertainties - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings.

The impacts on the Company’s and its affiliates’ operations and specifically the ongoing clinical trials of the Company’s pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

Although partially mitigated recently, there remains a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there remains a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets.

7

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Company has implemented a number of measures to protect the health and safety of the Company’s workforce including a voluntary work-from-home policy for the Company’s workforce who can perform their jobs from home as well as restrictions on business travel.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, the Company cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on the Company’s business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in the Company’s customers’ behavior emanating from the pandemic and how quickly the Company can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.

Investments

The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated.

Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.

Variable Interest Entities

In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.”

Equity Method Investments - RP Finance, LLC (“RP Finance”) (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.

8

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Revenue Recognition

The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation.

The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

Research and Development Costs

Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended.

Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

9

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS

Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings.

Pharma Holdings owns 50% of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Rafael Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma.

A trust for the benefit of the children of Howard Jonas (Chairman of the Board and former Chief Executive Officer of the Company and former Chairman of the Board of Rafael Pharmaceuticals) holds a financial instrument (the “Instrument”) that owns 10% of Pharma Holdings.

Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments.

On March 25, 2020, the Board of Directors of Rafael Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021 and on August 31, 2020, the Board of Directors of Rafael Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021.

Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019.

The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 41% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant).

The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.

The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions.

10

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures, to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting or consolidation and is carried at cost.

Rafael Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock.

The Instrument has additional contractual rights to receive additional Rafael Pharmaceuticals shares (“Bonus Shares”) for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Rafael Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment.

Pharma Holdings holds the Warrant to purchase a significant stake in Rafael Pharmaceuticals, as well as other equity and governance rights in Rafael Pharmaceuticals. The Company currently owns 51% of the issued and outstanding equity in Rafael Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant, which is non-dilutable and provides for the Company to increase its (via Pharma Holdings and CS Pharma and inclusive of the interests held by the other owners of those entities) total ownership to 56%. Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of April 30, 2021, the Company, and the Company’s affiliates, would need to pay approximately $17 million to exercise the Warrant in full to 56%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company and the Company’s affiliates would need to pay approximately $126 million to exercise the Warrant in full (including to offset the impact of additional issuances of Rafael Pharmaceuticals equity under the Line of Credit). The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant. Following any exercise, a portion of the Company’s interest in Rafael Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Given the Company’s anticipated available cash, the Company would not be able to exercise the Warrant in its entirety and the Company may never be able to exercise the Warrant in full. Rafael Pharmaceuticals may also issue additional equity interests, such as employee stock options, which will require the Company to pay additional cash to maintain the Company’s ownership percentage or exercise the Warrant in full.

On January 28, 2021, Pharma Holdings partially exercised the Warrant to maintain the 51% ownership percentage and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.

11

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 4 – INVESTMENT IN ALTIRA

The Company entered into its first Membership Interest Purchase Agreement (the “Purchase Agreement”) on May 13, 2020 with a member (the “First Seller”) of Altira Capital & Consulting, LLC (“Altira”). Pursuant to the Purchase Agreement, on May 13, 2020, the First Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 that was payable in four equal monthly installments of $250,000 each; 2) $3,000,000 payable on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made to the First Seller, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the 10 days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

The Company has accounted for the purchase of the 33.333% membership interest in Altira as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 33.333% membership interest in Altira indicates that the Company is able to exercise significant influence over Altira, and the Company’s membership interest is considered to be “more than minor” in accordance with the guidance. The cost of the investment was determined to be $4,000,000 pursuant to the terms of the Purchase Agreement. The contingent consideration, as described within the Purchase Agreement, in the amount of $6,000,000, will be recognized when the payments are considered probable.

For the fiscal year ended July 31, 2020, the Company determined that the investment in Altira was fully impaired and recorded an impairment charge of $4,000,000, which was the total amount of the Company’s investment recognized for the Purchase Agreement as of July 31, 2020.

On December 7, 2020, the Company purchased an additional 33.333% of membership interests in Altira, pursuant to the Membership Interest Purchase Agreement (the “Second Altira Agreement”) between the Company and another Altira member, (the “Second Seller”). With this transaction, the Company now owns a right to an aggregate 66.666% of the membership interests in Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Second Seller sold his economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive an additional 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the Membership Interest consists of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 payable on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.

Certain of the post-closing payments may be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the 10-day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

The purchase of the additional membership interests was accounted for as an asset acquisition, as Altira is not considered a business in accordance with the guidance in ASC 805, Business Combinations. The membership interests acquired do not consist of inputs, processes, and are not generating outputs, as required in ASC 805 to qualify as a business, and is therefore accounted for as an asset acquisition. Although this transaction is considered an asset acquisition, there are no assets or liabilities to be recorded as of the acquisition date as Altira does not have any business operations. The cost of the investment was determined to be $7,000,000 pursuant to the terms of the Second Altira Agreement.

12

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

For the nine months ended April 30, 2021, the Company determined that the additional purchase of the membership interests in Altira was fully impaired and recorded an impairment charge of $7,000,000, which was the total amount of the Company’s investment recognized for the Second Altira Agreement as of April 30, 2021.

During the nine months ended April 30, 2021, the Company issued 129,620 shares of Class B Common Stock totaling $3,500,000 to the First Seller for the Purchase Agreement.

Additionally, the Company issued 101,844 shares of Class B Common Stock totaling $2,750,000 to the Second Seller, and cash payments totaling $1,250,000 during the nine months ended April 30, 2021. The remaining payment due to the Second Seller, which is the contingent consideration as described within the Second Altira Agreement, of $3,000,000 is recorded as a current liability. The contingent consideration will be recognized when the payments are considered probable.

The assets and operations of Altira are not significant.

NOTE 5 – INVESTMENT IN RP FINANCE, LLC

On February 3, 2020, Rafael Pharmaceuticals entered into a Line of Credit Loan Agreement (“Line of Credit Agreement”) with RP Finance which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs.

The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals.

Under the Line of Credit Agreement, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earlier of February 3, 2025, upon a change of control of Rafael Pharmaceuticals or a sale of Rafael Pharmaceuticals or its assets. Rafael Pharmaceuticals can draw on the facility on 60 days’ notice. The funds borrowed under the Line of Credit Agreement must be repaid out of certain proceeds from equity sales by Rafael Pharmaceuticals.

In connection with entering into the Line of Credit Agreement, Rafael Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Rafael Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the Line of Credit Agreement.

RP Finance has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. Therefore, the Company will use the equity method of accounting to record the Company’s investment in RP Finance. The Company has recognized approximately $96 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance for the three months ended April 30, 2021 and 2020, respectively, and $288 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance for the nine months ended April 30, 2021 and 2020, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 11).

In August 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount of $5 million, paid in parts in August and September 2020. In November 2020, Rafael Pharmaceuticals called for a second $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount of $5 million. For the nine months ended April 30, 2021, the Company has funded a total of $3.75 million in accordance with its 37.5% ownership interest in RP Finance.

13

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 6 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

As of April 30, 2021, the Company held 68% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

In November 2019, the Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In January 2020, the Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In March 2020, the Company provided bridge financing in the principal amount of $75,000 to LipoMedix with a maturity date of April 20, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In May 2020, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 4,000,000 ordinary shares of LipoMedix for an aggregate purchase price of $1,000,000. The purchase consideration consisted of the outstanding Promissory Notes between the Company and LipoMedix dated November 13, 2019, January 21, 2020 and March 27, 2020 in the total principal amount of $300,000 plus accrued interest, for an aggregate amount of $306,737, and $693,263 of cash, thereby increasing the Company’s ownership in Lipomedix from 58% to 68%.

In March 2021, the Company provided bridge financing in the principal amount of up to $400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8% per annum. As of April 30, 2021, the Company has provided $270,379 of funding to LipoMedix. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

NOTE 7 – FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

● Level 1 - quoted prices in active markets for identical assets or liabilities;

● Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

● Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

14

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of April 30, 2021 and July 31, 2020:

	April 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	9,681	$	9,681
Total	$	—	$	—	$	9,681	$	9,681

	July 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:	(in thousands)
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

At April 30, 2021 and July 31, 2020, the Company did not have any liabilities measured at fair value on a recurring basis.

The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

	Nine Months Ended
	April 30,
	2021			2020
	(unaudited, in thousands)
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain included in earnings		4,171			492
Balance, end of period	$	9,681		$	5,617

Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. In October 2020, the Company received a $2 million distribution of the Company’s investments in Hedge Funds.

The Company holds $0.5 million in investments in securities in another entity that are not liquid, which were included in Investments - Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for under ASC 321, Investments - Equity Securities, using the measurement alternative as defined within the guidance, and the Company recorded an impairment loss of $0.7 million and $0.3 million for the nine months ended April 30, 2021 and 2020, respectively.

Fair Value of Other Financial Instruments

The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.

Cash and cash equivalents, trade accounts receivable, and accounts payable. At April 30, 2021 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1.

15

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 8 – TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Trade Accounts Receivable	$	287		$	364
Accounts Receivable - Related Party		144			121
Less Allowance for Doubtful Accounts		(183	)		(218	)
Trade Accounts Receivable, net	$	248		$	267

The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $101 thousand and $11 thousand as of April 30, 2021 and July 31, 2020, respectively.

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.4 million as of both April 30, 2021 and July 31, 2020.

NOTE 9 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Building and Improvements	$	47,814		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		270			256
		59,641			59,404
Less Accumulated Depreciation		(16,050	)		(14,971	)
Total	$	43,591		$	44,433

Other property and equipment consist of other equipment and miscellaneous computer hardware.

Depreciation expense pertaining to property and equipment was approximately $0.2 million and $0.5 million for the three months ended April 30, 2021 and 2020, respectively, and $1.1 million and $1.4 million for the nine months ended April 30, 2021 and 2020, respectively. 

The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey, where it occupies office space in the building owned by its subsidiary.

In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

16

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 10 – LOSS PER SHARE

Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per shares for the three and nine months ended April 30, 2021 and 2020 because all such securities are anti-dilutive for all periods presented.

The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

	Three months ended April 30,				Nine months ended April 30,
	2021		2020		2021		2020
Shares issuable upon exercise of stock options		689,210		580,874		689,210		580,874
Shares issuable upon exercise of warrants to purchase Class B common stock		26,189		—		26,189		—

The diluted loss per share computation equals basic loss per share for the three and nine months ended April 30, 2021 and 2020 because the Company had a net loss and the impact of the assumed exercise of stock options and warrants would have been anti-dilutive.

NOTE 11 – RELATED PARTY TRANSACTIONS

IDT Corporation

The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from various companies under common control to IDT. The Company recorded expense of approximately $91 thousand and $76 thousand in related party services to IDT for the three months ended April 30, 2021 and 2020, respectively, of which approximately $61 thousand and $27 thousand is included in Due to Related Parties at April 30, 2021 and 2020, respectively. The Company recorded expense of approximately $247 thousand and $232 thousand in related party services to IDT for the nine months ended April 30, 2021 and 2020, respectively, of which approximately $61 thousand and $27 thousand is included in Due to Related Parties at April 30, 2021 and 2020, respectively.

IDT leases approximately 80,000 square feet of office space plus parking at 520 Broad Street, Newark, New Jersey and approximately 3,600 square feet of office space in Jerusalem, Israel. IDT paid the Company approximately $461 thousand and $453 thousand for office rent and parking during each of the three months ended April 30, 2021 and 2020, respectively. IDT paid the Company approximately $1.38 million and $1.36 million for office rent and parking during each of the nine months ended April 30, 2021 and 2020, respectively. As of April 30, 2021 and 2020, IDT owed the Company approximately $152 thousand and $0, respectively, for office rent and parking.

During the three months ended April 30, 2021, IDT exercised 43,649 warrants to purchase shares of Class B Common Stock.

Rafael Pharmaceuticals

The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas served as the former Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $120 thousand for the three months ended April 30, 2021 and 2020, respectively, and $360 thousand for the nine months ended April 30, 2021 and 2020, respectively. As of April 30, 2021 and July 31, 2020, Rafael Pharmaceuticals owed the Company $480,000 and $118,000, respectively, included in Due from Rafael Pharmaceuticals.

17

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Levco Pharmaceuticals Ltd

On September 8, 2020, Levco Pharmaceuticals Ltd (“Levco”) entered into a research and development consulting agreement with Dr. Alberto Gabizon for a two-year period. Under the agreement, in exchange for the services provided, Levco will pay Dr. Gabizon $3,000 per month and issue to him common shares representing up to 5% of common stock outstanding. Additionally, Levco will provide a lab grant in the amount of $120,000 to support the project.

On September 8, 2020, Levco entered into a Sponsored Research Agreement with a company for a research program related to patent applications with payments totaling $120,000 plus value-added tax. The research period is over 13 months, with two additional 12-month options to extend.

Farber Partners LLC

On December 10, 2020, a controlled subsidiary of the Company, Farber, reached an agreement with Princeton University to in-license certain patents and related information related to the serine hydroxymethyltransferase (SHMT) inhibitor program developed by the laboratory of Dr. Joshua D. Rabinowitz at Princeton. Farber will pay Princeton a minimum annual royalty payment of $50 thousand, in addition to percentage royalties and a percentage of any sublicense revenue. Additionally, there are development milestone payments which Farber will pay Princeton for the first three products developed by Farber, or any sublicensees or affiliates.

Pharma Holdings

On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.

Related Party Rental Income

The Company leases space to related parties which represented approximately 62% and 43% of the Company’s total revenue for the three months ended April 30, 2021 and 2020, respectively, and 63% and 43% for the nine months ended April 30, 2021 and 2020, respectively. See Note 16 for future minimum rent payments from related parties and other tenants.

RP Finance

For the three months ended April 30, 2021 and 2020, the Company recognized approximately $96 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively. For the nine months ended April 30, 2021 and 2020, the Company recognized $288 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively (see Note 5).

Howard Jonas, Chairman of the Board and Former Chief Executive Officer

In December 2020, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. In connection with the purchases, each purchaser was granted warrants (the “Issued Warrants”) to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of $22.91 per share and expire on June 6, 2022. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

18

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 12 – INCOME TAXES

At April 30, 2021, the Company has federal net operating loss (“NOL”) carryforwards from domestic operations of approximately $44 million, to offset future taxable income. The Company has state NOLs of $27 million. The Company has NOLs from foreign operations of $3 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire.

The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s balances.

NOTE 13 – BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s CEO and chief operating decision-maker.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix, Barer, Levco, Farber, and Rafael Medical Devices are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

The Pharmaceuticals segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix, Barer, Levco, Farber, and Rafael Medical Devices. To date, the Pharmaceuticals segment has not generated any revenues.

The Real Estate segment consists of the Company’s real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage and a portion of an office building in Israel.

In August 2020, the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,658,000 in cash. At July 31, 2020, the building was classified as held for sale on the consolidated balance sheet.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended April 30, 2021
Revenues	$	—		$	990		$	990
Loss from operations		(1,417	)		(2,062	)		(3,479	)
Three Months Ended April 30, 2020
Revenues	$	—		$	1,224		$	1,224
Loss from operations		(778	)		(1,187	)		(1,965	)

19

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine Months Ended April 30, 2021
Revenues	$	—		$	3,002		$	3,002
Loss from operations		(10,593	)		(6,194	)		(16,787	)
Nine Months Ended April 30, 2020
Revenues	$	—		$	3,670		$	3,670
Loss from operations		(1,558	)		(3,855	)		(5,413	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Nine Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
April 30, 2021
Long-lived assets, net	$	42,048	$	1,543	$	43,591
Total assets		142,764		3,444		146,208
July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix’s bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds.

On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor, or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, New Jersey. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. On February 14, 2020, the Company entered into a Settlement Agreement with OSHA, as related to the citation received on July 12, 2019. As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021, which the Company accrued for and has an outstanding balance of approximately $32,000 as of April 30, 2021. As the Company accounts for contingencies when a loss is considered probable and can be reasonably estimated, the accrued balance is for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to additional loss may exist in excess of the amount accrued.

20

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

On December 31, 2019, an employee of the Company filed a complaint in connection with the incident that led to the OSHA inspection noted above for personal injuries against the Company and other parties in the New Jersey Supreme Court for an incident that took place on January 31, 2019 at 520 Broad Street, Newark, New Jersey. The Company intends to vigorously defend this matter. The loss is considered remote and no accrual has been recorded.

The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, other than noted above, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition.

NOTE 15 – EQUITY

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million that was convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. In August 2019, the note, including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock.

Pursuant to the Company’s 2018 Equity Incentive Plan, three of the Company’s four non-employee directors of the Company were granted 4,203 restricted shares of Class B common stock in January 2021 and 4,203 restricted shares of Class B common stock in January 2020 which fully vested on the date of the grants. The fair value of the awards on the date of the grants were approximately $286,000 and $208,000 in January 2021 and January 2020, respectively, which was included in Selling, General and Administrative Expense.

Stock Options

A summary of stock option activity for the Company is as follows: 

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	5,269
Granted		118,409			40.85		10.00		176
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(1,323	)		—
Outstanding at April 30, 2021		689,210		$	11.08		3.29	$	21,547
Exercisable at April 30, 2021		570,801		$	4.90		1.91	$	21,371

During April 2021, 118,409 options were granted to one individual, resulting in $0.7 million in stock-based compensation expense for the three months ended April 30, 2021. These options are subject to graded vesting extending through April 15, 2025.

During the nine months ended April 30, 2021, 8,750 options were exercised. At April 30, 2021, there was unrecognized compensation cost related to non-vested stock options of $2.9 million, which is expected to be recognized over the next 2.1 years.

21

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Restricted Stock

The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service.

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		44,070			21.92
Vested		(69,347	)		10.76
Cancelled / Forfeited		(2,099	)		13.54
Non-vested shares at April 30, 2021		95,728		$	15.28

At April 30, 2021, there was $1.6 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 2.4 years.

Share Purchase Agreement

On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the “SPA”) for the sale of 567,437 shares of the Company’s Class B common stock at a price per share of $22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020, the trading day immediately preceding the date of the SPA) for an aggregate purchase price of $13 million.

Approximately $8.2 million of the proceeds received pursuant to the SPA were used by the Company to exercise an additional portion of the Warrant in order to maintain the Company’s relative position in Rafael Pharmaceuticals in light of issuances of Rafael Pharmaceuticals equity securities to third-party shareholders of Rafael Pharmaceuticals, due to warrant exercises by these shareholders. The Company is using the remaining proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

Equity-classified Warrants

In connection with the Share Purchase Agreement, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Company issued warrants to purchase 113,487 shares of Class B common stock to the purchasers. The warrants are exercisable at a per share exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022. The Company determined that these warrants are equity-classified.

During the three months ended April 30, 2021, IDT and Genie Energy, Ltd each exercised 43,649 warrants, resulting in a total of 87,298 shares of Class B common stock issued for proceeds of approximately $2 million. At April 30, 2021, the Company had outstanding warrants to purchase 26,189 shares of Class B common stock at an exercise price of $22.91 per share, all of which expire June 6, 2022.

22

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 16 – LEASES

The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029. Lease income included on the consolidated statements of operations and comprehensive loss was $0.8 million and $0.9 million for the three months ended April 30, 2021 and 2020, respectively, and $2.2 million and $2.6 million for the nine months ended April 30, 2021 and 2020, respectively.

The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of April 30, 2021, under non-cancellable operating leases which expire on various dates through 2028 are as follows:

Year ending July 31,	Related Parties		Other		Total
	(in thousands)
2021 (remaining)	$	516	$	179	$	695
2022		2,078		782		2,860
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	8,525	$	4,589	$	13,114

The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

NOTE 17 – SUBSEQUENT EVENTS

On May 27, 2021, the Company granted 908,497 restricted shares of Class B common stock of the Company to the Chief Executive Officer. Additionally, in June 2021, the Company paid a $2 million sign-on bonus to the Chief Executive Officer.

On May 27, 2021, the Company filed its Shelf Registration on Form S-3, whereby the Company may sell up to $250 million of Class B common stock. This registration was declared effective on June 7, 2021.

On May 31, 2021, the Company received a $5 million distribution of the Company’s investment in Hedge Funds.

On June 1, 2021, the Company issued 48,859 shares of Class B common stock to the Altira Second Seller totaling $2.25 million to satisfy a portion of the remaining non-contingent obligation due to the Altira Second Seller.

On June 2, 2021, the Company paid $750 thousand in cash to the Altira Second Seller to satisfy the remaining non-contingent obligation due to the Altria Second Seller.

On June 3, 2021, the Company provided $1.875 million of additional funding to RP Finance.

23

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We own interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business.

The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells; and, a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, we established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions. In addition, we have recently initiated efforts to develop other early stage pharmaceutical ventures including Levco, an Israeli company, established to partner with Dr. Alberto Gabizon and a top institution in Israel on the development of novel compounds for cancer, and Farber Partners, formed around an agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program. Additionally, in 2021, we established Rafael Medical Devices, a wholly-owned orthopedic device company developing instruments and implants to advance minimally invasive surgeries in the upper and lower extremities.

The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain other entities and hosts other tenants and an associated 800-car public garage, and a portion of a building in Israel. In August 2020, we sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

Business Update - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, has since spread around the globe. We actively monitor the outbreak and its potential impact on our operations and those of our holdings.

The impacts on our and our affiliates’ operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

Although partially mitigated recently, there remains a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there remains a potential impact to the value of our real estate portfolio as well as efforts to monetize those assets.

We have implemented a number of measures to protect the health and safety of our workforce including a voluntary work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of our holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, we may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business.

24

Results of Operations

Our business consists of two reportable segments - Pharmaceuticals and Real Estate. We evaluate the performance of our Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and our Real Estate segment based primarily on results of operations. Accordingly, the income and expense line items below loss from operations are only included in the discussion of consolidated results of operations.

Three and Nine Months Ended April 30, 2021 Compared to Three and Nine Months Ended April 30, 2020

Pharmaceuticals Segment

Our consolidated expenses for our Pharmaceuticals segment were as follows:

	Three Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Selling, general and administrative	$	(154	)	$	(144	)	$	(10	)		(7	)%
Research and development		(1,262	)		(634	)		(628	)		(99	)%
Depreciation		(1	)		—			(1	)		(100	)%
Impairment – Altira		—			—			—			—	%
Loss from operations	$	(1,417	)	$	(778	)	$	(639	)		(82	)%

	Nine Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Selling, general and administrative	$	(247	)	$	(230	)	$	(17	)		(7	)%
Research and development		(3,345	)		(1,327	)		(2,018	)		(152	)%
Depreciation		(1	)		(1	)		—			—	%
Impairment – Altira		(7,000	)		—			(7,000	)		(100	)%
Loss from operations	$	(10,593	)	$	(1,558	)	$	(9,035	)		(580	)%

To date, the Pharmaceuticals segment has not generated any revenues. The entirety of the expenses in the Pharmaceuticals segment relate to the activities of LipoMedix, Barer, Levco, Farber, and Rafael Medical Devices. Research and development increased for the three and nine months ended April 30, 2021 compared to the three and nine months ended April 30, 2020 due to increased Barer, Levco, Farber, and Rafael Medical Devices activity. We recorded an impairment expense of $7.0 million related to our purchase of a 33.333% membership interest in Altira for the nine months ended April 30, 2021. As of April 30, 2021 and 2020, we held a 68% and 58% interest, respectively, in LipoMedix, a 95% and 0% interest in Levco, respectively, and a 93% and 0% interest in Farber, respectively. We consolidated our majority interests in Lipomedix, Levco, and Farber.

25

Real Estate Segment

Our consolidated income and expenses for our Real Estate segment were as follows:

	Three Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Rental – Third Party	$	228		$	360		$	(132	)		(37	)%
Rental – Related Party		523			523			—			—	%
Parking		119			221			(102	)		(46	)%
Other		120			120			—			—	%
Selling, general and administrative		(2,852	)		(1,937	)		(915	)		(47	)%
Depreciation		(200	)		(474	)		274			58	%
Loss from operations	$	(2,062	)	$	(1,187	)	$	(875	)		(74	)%

	Nine Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Rental – Third Party	$	654		$	1,076		$	(422	)		(39	)%
Rental – Related Party		1,570			1,570			—			—	%
Parking		418			664			(246	)		(37	)%
Other		360			360			—			—	%
Selling, general and administrative		(8,118	)		(6,113	)		(2,005	)		(33	)%
Depreciation		(1,078	)		(1,412	)		334			24	%
Loss from operations	$	(6,194	)	$	(3,855	)	$	(2,339	)		(61	)%

Revenues. Rental and Parking revenues decreased by approximately $234 thousand and $668 thousand for the three and nine months ended April 30, 2021 compared to the three and nine months ended April 30, 2020 primarily due to the sale of the building in Piscataway and the related reduced rental income, in addition to the decrease in parking as many customers who were utilizing the parking garage are now working from home due to COVID-19.

Selling, general and administrative expenses. Selling, general and administrative expenses consist mainly of payroll, benefits, facilities, consulting and professional fees. The increase in selling, general and administrative expenses for the three and nine months ended April 30, 2021 compared to the three and nine months ended April 30, 2020 is primarily due to increased insurance, payroll, and real estate tax costs.

Depreciation expenses. Depreciation expenses decreased for the three and nine months ended April 30, 2021 as compared to the three and nine months ended April 30, 2020 due to the sale of the building in Piscataway, New Jersey.

26

Consolidated Operations

Our consolidated income and expense line items below income from operations were as follows:

	Three Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Loss from operations	$	(3,479	)	$	(1,965	)	$	(1,514	)		(77	)%
Interest expense, net		(1	)		—			(1	)		100	%
Impairment of investments - Other Pharmaceuticals		—			(295	)		295			(100	)%
Unrealized gain (loss) on investments - Hedge Funds		738			(28	)		766			(2736	)%
Loss before income taxes		(2,742	)		(2,288	)		(454	)		(20	)%
Provision for income taxes		(4	)		(8	)		4			50	%
Equity in earnings of RP Finance		96			53			43			81	%
Consolidated net loss		(2,650	)		(2,243	)		(407	)		(18	)%
Net loss attributable to noncontrolling interests		(97	)		(84	)		(13	)		(15	)%
Net loss attributable to Rafael Holdings, Inc.	$	(2,553	)	$	(2,159	)	$	(394	)		(18	)%

	Nine Months Ended April 30,						Change
	2021			2020			$			%
	(unaudited, in thousands)
Loss from operations	$	(16,787	)	$	(5,413	)	$	(11,374	)		(210	)%
Interest expense, net		(2	)		(31	)		29			94	%
Net loss resulting from foreign exchange transactions		—			(5	)		5			100	%
Gain on sale of building		749			—			749			100	%
Impairment of investments - Other Pharmaceuticals		(724	)		(295	)		(429	)		145	%
Unrealized gain on investments - Hedge Funds		4,171			492			3,679			748	%
Loss before income taxes		(12,593	)		(5,252	)		(7,341	)		(140	)%
Provision for income taxes		(13	)		(24	)		11			46	%
Equity in earnings of RP Finance		288			53			235			443	%
Consolidated net loss		(12,318	)		(5,223	)		(7,095	)		(136	)%
Net loss attributable to noncontrolling interests		(154	)		(213	)		59			28	%
Net loss attributable to Rafael Holdings, Inc.	$	(12,164	)	$	(5,010	)	$	(7,154	)		(143	)%

Interest expense, net. Interest expense, net was $(1) thousand for the three months ended April 30, 2021 and $0 for the three months ended April 30, 2020. The reduction of interest income is due to interest earned for the three months ended April 30, 2020 on a Certificate of Deposit (“CD”) account that was subsequently closed and funds transferred to fund the Warrant exercise. Interest (expense) income, net was $(2) thousand for the nine months ended April 30, 2021 and $(31) thousand for the nine months ended April 30, 2020. The reduction of interest expense during the nine months ended April 30, 2021 is due to the conversion of the $15.0 million convertible note and related interest, to equity, during the prior fiscal year.

Net loss resulting from foreign exchange transactions. Net loss resulting from foreign exchange transactions is composed entirely from changes in movements in New Israeli Shekels relative to the U.S. Dollar.

Gain on sale of building. In August 2020, we sold a building located in Piscataway, New Jersey, and recognized a gain on the sale of approximately $749 thousand.

27

Impairment of investments - Other Pharmaceuticals. We recorded an impairment loss of $724 thousand related to our investment using the measurement alternative for the nine months ended April 30, 2021.

Unrealized gain (loss) on investments - Hedge Funds. We recorded unrealized gains (losses) of approximately $0.7 million and $(28) thousand for the three months ended April 30, 2021 and 2020, respectively, and approximately $4.2 million and $492 thousand for the nine months ended April 30, 2021 and 2020, respectively.

Equity in earnings of RP Finance. We recognized approximately $96 thousand and $288 thousand in income from its ownership interests of 37.5% in RP Finance for the three and nine months ended April 30, 2021, respectively.

Net loss (income) attributable to noncontrolling interests. The change in the net loss (income) attributable to noncontrolling interests was due to LipoMedix, and the new entities Farber and Levco for the three and nine months ended April 30, 2021.

Liquidity and Capital Resources

General

As of April 30, 2021, we had cash and cash equivalents of $4.7 million. We expect our cash from operations in the next 12 months, the balance of cash and cash equivalents that we held as of April 30, 2021, and our balance in Investments – Hedge Funds of $9.7 million as of April 30, 2021 to be sufficient to meet our currently anticipated working capital, research and development, and capital expenditure requirements during the next 12 months from the issuance of these consolidated financial statements. Additionally, the Company filed its Shelf Registration on Form S-3 on May 27, 2021, authorizing the sale of up to $250 million of Class B common stock. This registration was declared effective as of June 7, 2021.

	April 30,
	2021			2020
	(unaudited, in thousands)
Cash flows (used in) provided by
Operating activities	$	(8,620	)	$	(2,975	)
Investing activities		(8,702	)		(491	)
Financing activities		15,770			(96	)
Effect of exchange rates on cash and cash equivalents		25			(32	)
Decrease in cash and cash equivalents	$	(1,527	)	$	(3,594	)

Operating Activities

The increase in cash used in operating activities for the nine months ended April 30, 2021 as compared to the nine months ended April 30, 2020 was primarily related to the net loss, and impact from noncash items, primarily the impairment expense related to the investment in Altira of $7.0 million and the increase in stock based compensation of $1.0 million, offset by the unrealized gain on investments - Hedge Funds of $4.2 million.

Investing Activities

Cash used in investing activities for the nine months ended April 30, 2021 was primarily related to our partial exercise of the Warrant and purchasing 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, the payments to fund our portion of advances under the line of credit between RP Finance and Rafael Pharmaceuticals, the payments of $1.3 million towards the acquisition of a second 33.333% membership interest in Altira for a product-in-development, and payments of $3.75 million to RP Finance in accordance with our 37.5% ownership interest, offset by the proceeds of $3.7 million from the sale of the building in Piscataway, New Jersey in August 2020 and proceeds of $2.0 million from liquidation of hedge funds.

Cash used in investing activities for the nine months ended April 30, 2020 related to building improvements made to our real estate holdings.

28

Financing Activities

Cash provided by financing activities for the nine months ended April 30, 2021 was primarily related to proceeds of $13.0 million for the sale of 567,437 shares of our Class B common stock and warrants to purchase an additional 113,487 shares of Class B common stock. Additionally, there were approximately $2.0 million in proceeds provided by the exercise of 87,298 warrants.

Cash used in financing activities for the nine months ended April 30, 2020 was due to payments for taxes related to shares withheld for employee taxes on a restricted stock vest.

We do not anticipate paying dividends on our common stock until we achieve sustainable profitability and retain certain minimum cash reserves. The payment of dividends in any specific period will be at the sole discretion of our Board of Directors.

Trends and Uncertainties – COVID-19

In December 2019, a novel strain of COVID-19 emerged and has subsequently expanded to a pandemic resulting in significant risks and disruptions to the health and welfare of the global population and economy. For the period ended October 31, 2020, COVID-19 has not had a material impact on our operations, and we anticipate that our existing balances of cash and cash equivalents and cash flows expected to be generated from our operations will be sufficient to satisfy our operating requirements for at least the next 12 months.

We actively monitor the outbreak and its potential impact on our operations and those of our holdings. Although our operations are mainly in the United States, we have assets outside of the United States, and some of our pharmaceutical holdings conduct operations, manufacturing and clinical trial activities in Europe and Asia.

The impacts on our and our affiliates’ operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

Although partially mitigated recently, there remains a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there remains a potential impact to the value of our real estate portfolio as well as efforts to monetize those assets.

We have implemented a number of measures to protect the health and safety of our workforce including a voluntary work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of our holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, we may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business.

29

Critical Accounting Policies and Estimates

We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial condition in conformity with U.S. GAAP. We apply these accounting policies in a consistent manner. Our significant accounting policies are discussed in Note 1, “Description of Business and Summary of Significant Accounting Policies,” to our consolidated financial statements included in our 2020 Form 10-K.

The application of critical accounting policies requires that we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. These estimates and assumptions are based on historical and other factors believed to be reasonable under the circumstances. We evaluate these estimates and assumptions on an ongoing basis and may retain outside consultants to assist in our evaluation. If actual results ultimately differ from previous estimates, the revisions are included in results of operations in the period in which the actual amounts become known. The critical accounting policies that involve the most significant management judgments and estimates used in preparation of our consolidated financial statements, or are the most sensitive to change from outside factors, are discussed in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Company’s Annual Report on Form 10-K for fiscal 2020 (“2020 Form 10-K”). There have been no material changes in our critical accounting policies and procedures during the nine months ended April 30, 2021.

Off-Balance Sheet Arrangements

We do not have any “off-balance sheet arrangements,” as defined in relevant SEC regulations that are reasonably likely to have a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

IDT is generally responsible for our federal, state, local and foreign income taxes for periods before and including the Spin-Off. We are generally responsible for all other taxes relating to our business. We and IDT will each generally be responsible for managing those disputes that relate to the taxes for which each of us is responsible and, under certain circumstances, may jointly control any dispute relating to taxes for which both of us are responsible.

Item 3. Quantitative and Qualitative Disclosures about Market Risks

There have been no significant changes in our market risk exposures from those described in Item 7A of our 2020 Form 10-K.

We are monitoring the potential impacts of the COVID-19 pandemic on our business. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may reduce our ability to access capital, which could negatively impact our long-term liquidity.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of April 30, 2021.

Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting during the quarter ended April 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

30

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

Legal proceedings in which we are involved are more fully described in Note 14 to the Consolidated Financial Statements included in Item 1 to Part I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

Item 1A Risk Factors contained in our 2020 Form 10-K includes a discussion of risk factors related to investment in our common stock which is incorporated herein. There were no material changes from the risk factors associated with our business previously disclosed in Part I, Item 1A “Risk Factors” of our 2020 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

31

Item 6. Exhibits

Exhibit Number	Description
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document

* Filed or furnished herewith.

32

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 14, 2021	Rafael Holdings, Inc.
	By:	/s/ Ameet Mallik
		Ameet Mallik Chief Executive Officer
	By:	/s/ David Polinsky
		David Polinsky Chief Financial Officer

33

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ameet Mallik, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2021

/s/ Ameet Mallik

Ameet Mallik

Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Polinsky, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2021

/s/ David Polinsky

David Polinsky

Chief Financial Officer

EX-32.1

EXHIBIT 32.1

Certification Pursuant to

18 U.S.C. Section 1350

(as Adopted Pursuant to Section 906 of

the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended April 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Ameet Mallik, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2021

/s/ Ameet Mallik

Ameet Mallik

Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

EXHIBIT 32.2

Certification Pursuant to

18 U.S.C. Section 1350

(as Adopted Pursuant to Section 906 of

the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended April 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, David Polinsky, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2021

/s/ David Polinsky

David Polinsky

Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2021	Jun. 14, 2021
Document Information Line Items
Entity Registrant Name	Rafael Holdings, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Amendment Flag	false
Entity Central Index Key	0001713863
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Apr. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	000-55863
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Class A common stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		787,163
Class B common stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		16,927,318

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 4,679	$ 6,206
Trade accounts receivable, net of allowance for doubtful accounts of $183 and $218 at April 30, 2021 and July 31, 2020, respectively	248	267
Due from Rafael Pharmaceuticals	480	118
Prepaid expenses and other current assets	625	273
Assets held for sale		2,968
Total current assets	6,032	9,832
Property and equipment, net	43,591	44,433
Equity investment – RP Finance LLC	479	192
Due from RP Finance LLC	3,750
Investments – Rafael Pharmaceuticals	79,141	70,018
Investments – Other Pharmaceuticals	477	1,201
Investments – Hedge Funds	9,681	7,510
Deferred income tax assets, net		6
In-process research and development and patents	1,575	1,575
Other assets	1,482	1,580
TOTAL ASSETS	146,208	136,347
CURRENT LIABILITIES
Trade accounts payable	753	921
Accrued expenses	861	1,191
Amount due for purchase of membership interest	3,000	3,500
Other current liabilities	235	115
Due to related parties	60
Total current liabilities	4,909	5,727
Deferred income tax liabilities, net	9
Other liabilities	33	92
TOTAL LIABILITIES	4,951	5,819
COMMITMENTS AND CONTINGENCIES
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2021 and July 31, 2020, respectively	8	8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 15,969,962 issued and 15,982,349 outstanding as of April 30, 2021, and 15,034,598 issued and 15,028,536 outstanding as of July 31, 2020	158	149
Additional paid-in capital	151,258	129,136
Accumulated deficit	(28,419)	(16,255)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,766	3,762
Total equity attributable to Rafael Holdings, Inc.	126,771	116,800
Noncontrolling interests	14,486	13,728
TOTAL EQUITY	141,257	130,528
TOTAL LIABILITIES AND EQUITY	$ 146,208	$ 136,347

XML

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Allowance for doubtful accounts (in Dollars)	$ 183	$ 218
Class A common stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B common stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,969,962	15,034,598
Common stock, shares outstanding	15,982,349	15,028,536

XML

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
REVENUE
Rental - Third Party	$ 228	$ 360	$ 654	$ 1,076
Rental - Related Party	523	523	1,570	1,570
Parking	119	221	418	664
Other - Related Party	120	120	360	360
Total revenue	990	1,224	3,002	3,670
COSTS AND EXPENSES
Selling, general and administrative	3,006	2,081	8,365	6,343
Research and development	1,262	634	3,345	1,327
Depreciation and amortization	201	474	1,079	1,413
Impairment - Altira			7,000
Loss from operations	(3,479)	(1,965)	(16,787)	(5,413)
Interest expense, net	(1)		(2)	(31)
Net loss resulting from foreign exchange transactions				(5)
Gain on sale of building			749
Impairment of investments - Other Pharmaceuticals		(295)	(724)	(295)
Unrealized gain (loss) on investments - Hedge Funds	738	(28)	4,171	492
Loss before income taxes	(2,742)	(2,288)	(12,593)	(5,252)
Provision for income taxes	(4)	(8)	(13)	(24)
Equity in earnings of RP Finance	96	53	288	53
Consolidated net loss	(2,650)	(2,243)	(12,318)	(5,223)
Net loss attributable to noncontrolling interests	(97)	(84)	(154)	(213)
Net loss attributable to Rafael Holdings, Inc.	(2,553)	(2,159)	(12,164)	(5,010)
OTHER COMPREHENSIVE LOSS
Net loss	(2,650)	(2,243)	(12,318)	(5,223)
Foreign currency translation adjustment	5	(4)	4	(32)
Total comprehensive loss	(2,645)	(2,247)	(12,314)	(5,255)
Comprehensive loss attributable to noncontrolling interests	(28)	(3)	(39)	(19)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$ (2,617)	$ (2,244)	$ (12,275)	$ (5,236)
Loss per share
Basic and diluted (in Dollars per share)	$ (0.15)	$ (0.14)	$ (0.75)	$ (0.32)
Weighted average number of shares used in calculation of loss per share
Basic and diluted (in Shares)	16,668,624	15,813,679	16,216,969	15,747,709

XML

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Additional Paid-in Capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests	Common Stock, Series A	Common Stock, Series B
Balance, at Jul. 31, 2019	$ 124,764	$ 112,898	$ (5,840)	$ 3,784	$ 13,783	$ 8	$ 131
Balance, (in Shares) at Jul. 31, 2019						787,163	13,142,502
Net loss	(5,223)		(5,010)		(213)
Stock-based compensation	338	338
Stock-based compensation (in Shares)							24,071
Stock-based compensation to Board of Directors	208	208
Stock-based compensation to Board of Directors (in Shares)							12,609
Shares issued for convertible debt	15,668	15,650					$ 18
Shares issued for convertible debt (in Shares)							1,849,749
Shares withheld for payroll taxes	(125)	(125)
Shares withheld for payroll taxes (in Shares)							(6,062)
Stock options exercised	29	29
Stock options exercised (in Shares)							6,000
Conversion of LipoMedix bridge notes	200				200
Foreign currency translation adjustment	(32)			(32)
Balance, at Apr. 30, 2020	135,827	128,998	(10,850)	3,752	13,770	$ 8	$ 149
Balance, (in Shares) at Apr. 30, 2020						787,163	15,028,869
Balance, at Jan. 31, 2020	137,919	128,843	(8,691)	3,756	13,854	$ 8	$ 149
Balance, (in Shares) at Jan. 31, 2020						787,163	15,020,485
Net loss	(2,243)		(2,159)		(84)
Stock-based compensation	135	135
Stock-based compensation (in Shares)							3,208
Shares withheld for payroll taxes	(9)	(9)
Shares withheld for payroll taxes (in Shares)							(824)
Stock options exercised	29	29
Stock options exercised (in Shares)							6,000
Foreign currency translation adjustment	(4)			(4)
Balance, at Apr. 30, 2020	135,827	128,998	(10,850)	3,752	13,770	$ 8	$ 149
Balance, (in Shares) at Apr. 30, 2020						787,163	15,028,869
Balance, at Jul. 31, 2020	130,528	129,136	(16,255)	3,762	13,728	$ 8	$ 149
Balance, (in Shares) at Jul. 31, 2020						787,163	15,028,536
Net loss	(12,318)		(12,164)		(154)
Stock-based compensation	737	737
Stock-based compensation (in Shares)							41,082
Stock-based compensation to Board of Directors	286	286
Stock-based compensation to Board of Directors (in Shares)							12,609
Shares issued - Securities Purchase Agreements	13,000	12,994					$ 6
Shares issued - Securities Purchase Agreements (in Shares)							567,437
Shares issued - Investment in Altira	6,250	6,248					$ 2
Shares issued - Investment in Altira (in Shares)							231,464
Shares withheld for payroll taxes	(185)	(185)
Shares withheld for payroll taxes (in Shares)							(7,214)
Warrants exercised	2,000	1,999					$ 1
Warrants exercised (in Shares)							87,298
Stock options exercised	43	43
Stock options exercised (in Shares)							8,750
Capital contribution for noncontrolling interest	912				912
Foreign currency translation adjustment	4			4
Balance, at Apr. 30, 2021	141,257	151,258	(28,419)	3,766	14,486	$ 8	$ 158
Balance, (in Shares) at Apr. 30, 2021						787,163	15,969,962
Balance, at Jan. 31, 2021	135,387	142,746	(25,866)	3,761	14,583	$ 8	$ 155
Balance, (in Shares) at Jan. 31, 2021						787,163	15,652,120
Net loss	(2,650)		(2,553)		(97)
Stock-based compensation	304	304
Shares issued - Investment in Altira	6,250	6,248					$ 2
Shares issued - Investment in Altira (in Shares)							231,464
Shares withheld for payroll taxes	(39)	(39)
Shares withheld for payroll taxes (in Shares)							(920)
Warrants exercised	2,000	1,999					$ 1
Warrants exercised (in Shares)							87,298
Foreign currency translation adjustment	5			5
Balance, at Apr. 30, 2021	$ 141,257	$ 151,258	$ (28,419)	$ 3,766	$ 14,486	$ 8	$ 158
Balance, (in Shares) at Apr. 30, 2021						787,163	15,969,962

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Operating activities
Net loss	$ (12,318)	$ (5,223)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,079	1,413
Deferred income taxes	15	13
Net unrealized gain on investments - Hedge Funds	(4,171)	(492)
Impairment of investments - Other Pharmaceuticals	724	295
Impairment - Altira	7,000
Equity in earnings of RP Finance	(288)	(53)
(Recovery of) provision for doubtful accounts	(183)	48
Stock-based compensation	1,023	546
Amortization of debt discount		54
Gain on sale of building	(749)
Change in assets and liabilities:
Trade accounts receivable	202	141
Prepaid expenses and other current assets	(352)	171
Other assets	98	(72)
Accounts payable and accrued expenses	(459)	28
Other current liabilities	120
Due to related parties	60	107
Due from Rafael Pharmaceuticals	(362)
Accrued interest - related party		19
Other liabilities	(59)	30
Net cash used in operating activities	(8,620)	(2,975)
Investing activities
Investment in Altira	(1,250)
Purchases of property and equipment	(237)	(491)
Payments to fund RP Finance	(3,750)
Proceeds from sale of building	3,658
Proceeds related to distribution from Hedge Funds	2,000
Investment in Rafael Pharmaceuticals	(9,123)
Net cash used in investing activities	(8,702)	(491)
Financing activities
Contribution from noncontrolling interest of consolidated entity	912
Proceeds from exercise of options	43	29
Proceeds from exercise of warrants	2,000
Proceeds from issuance of shares	13,000
Payments for taxes related to shares withheld for employee taxes	(185)	(125)
Net cash provided by (used in) financing activities	15,770	(96)
Effect of exchange rate changes on cash and cash equivalents	25	(32)
Net decrease in cash and cash equivalents	(1,527)	(3,594)
Cash and cash equivalents, beginning of period	6,206	12,024
Cash and cash equivalents, end of period	4,679	8,430
Supplemental schedule of noncash investing and financing activities
Common shares issued for payment of purchase price for Altira equity	6,250
Conversion of LipoMedix bridge notes		200
Conversions of related party convertible notes payable and accrued interest		$ 15,668

XML

Description of Business

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 – DESCRIPTION OF BUSINESS

Rafael Holdings, Inc. (“Rafael Holdings” or the “Company”), a Delaware corporation, owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business.

The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells; and, a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, the Company established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions. In addition, the Company has recently initiated efforts to develop other early stage pharmaceutical ventures including Levco Pharmaceuticals Ltd. (“Levco”), an Israeli company, established to partner with Dr. Alberto Gabizon and a top institution in Israel on the development of novel compounds for cancer, and Farber Partners, LLC (“Farber”), formed around an agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program. Additionally, in 2021, the Company established Rafael Medical Devices, LLC (“Rafael Medical Devices”), a wholly-owned orthopedic device company developing instruments and implants to advance minimally invasive surgeries in the upper and lower extremities.

The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain other entities and hosts other tenants and an associated 800-car public garage, and a portion of a building in Israel. In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

The “Company” in these consolidated financial statements refers to Rafael Holdings on a consolidated basis. All significant intercompany accounts and transactions have been eliminated in consolidation.

All majority-owned subsidiaries are consolidated with all intercompany transactions and balances eliminated in consolidation or combination. The entities included in these consolidated financial statements are as follows:

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware	100	%
Broad Atlantic Associates, LLC	United States – Delaware	100	%
IDT 225 Old NB Road, LLC	United States – Delaware	100	%
IDT R.E. Holdings Ltd.	Israel	100	%
Rafael Holdings Realty, Inc.	United States – Delaware	100	%
Barer Institute, Inc.	United States – Delaware	100	%
The Barer Institute, LLC	United States – Delaware	100	%
Hillview Avenue Realty, JV	United States – Delaware	100	%
Hillview Avenue Realty, LLC	United States – Delaware	100	%
Rafael Medical Devices, LLC	United States – Delaware	100	%
Levco Pharmaceuticals Ltd.	Israel	95	%
Farber Partners, LLC	United States – Delaware	93	%
Pharma Holdings, LLC	United States – Delaware	90	%
LipoMedix Pharmaceuticals Ltd.	Israel	68	%
Altira Capital & Consulting, LLC	United States – Delaware	67	%
CS Pharma Holdings, LLC	United States – Delaware	45	%*

* 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

XML

Summary of Significant Accounting Policies

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020).

Operating results for the three and nine months ended April 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (the “SEC”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.

Liquidity

Management believes that its cash on hand, planned forecast, and expected ability to meet its obligations alleviates the substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of the issuance of these financial statements. The Company has no outstanding long term debt due within 12 months and has cash reserves which will enable it to meet obligations for over a year, without attempt to monetize assets via increasing building occupancy or selling assets. The Company can liquidate its investments in hedge funds to generate cash if needed, and the Company could consider alternative sources of funding if necessary.

Risks and Uncertainties - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings.

The impacts on the Company’s and its affiliates’ operations and specifically the ongoing clinical trials of the Company’s pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

Although partially mitigated recently, there remains a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there remains a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets.

The Company has implemented a number of measures to protect the health and safety of the Company’s workforce including a voluntary work-from-home policy for the Company’s workforce who can perform their jobs from home as well as restrictions on business travel.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, the Company cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on the Company’s business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in the Company’s customers’ behavior emanating from the pandemic and how quickly the Company can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.

Investments

The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated.

Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.

Variable Interest Entities

In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.”

Equity Method Investments - RP Finance, LLC (“RP Finance”) (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.

Revenue Recognition

The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation.

The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

Research and Development Costs

Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended.

Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

XML

Investment in Rafael Pharmaceuticals

9 Months Ended

Apr. 30, 2021

Schedule of Investments [Abstract]

INVESTMENT IN RAFAEL PHARMACEUTICALS

NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS

Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings.

Pharma Holdings owns 50% of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Rafael Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma.

A trust for the benefit of the children of Howard Jonas (Chairman of the Board and former Chief Executive Officer of the Company and former Chairman of the Board of Rafael Pharmaceuticals) holds a financial instrument (the “Instrument”) that owns 10% of Pharma Holdings.

Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments.

On March 25, 2020, the Board of Directors of Rafael Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021 and on August 31, 2020, the Board of Directors of Rafael Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021.

Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019.

The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 41% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant).

The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.

The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions.

The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures, to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting or consolidation and is carried at cost.

Rafael Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock.

The Instrument has additional contractual rights to receive additional Rafael Pharmaceuticals shares (“Bonus Shares”) for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Rafael Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment.

Pharma Holdings holds the Warrant to purchase a significant stake in Rafael Pharmaceuticals, as well as other equity and governance rights in Rafael Pharmaceuticals. The Company currently owns 51% of the issued and outstanding equity in Rafael Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant, which is non-dilutable and provides for the Company to increase its (via Pharma Holdings and CS Pharma and inclusive of the interests held by the other owners of those entities) total ownership to 56%. Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of April 30, 2021, the Company, and the Company’s affiliates, would need to pay approximately $17 million to exercise the Warrant in full to 56%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company and the Company’s affiliates would need to pay approximately $126 million to exercise the Warrant in full (including to offset the impact of additional issuances of Rafael Pharmaceuticals equity under the Line of Credit). The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant. Following any exercise, a portion of the Company’s interest in Rafael Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Given the Company’s anticipated available cash, the Company would not be able to exercise the Warrant in its entirety and the Company may never be able to exercise the Warrant in full. Rafael Pharmaceuticals may also issue additional equity interests, such as employee stock options, which will require the Company to pay additional cash to maintain the Company’s ownership percentage or exercise the Warrant in full.

On January 28, 2021, Pharma Holdings partially exercised the Warrant to maintain the 51% ownership percentage and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.

XML

Investment in Altira

9 Months Ended

Apr. 30, 2021

Investment In Altira [Abstract]

INVESTMENT IN ALTIRA

NOTE 4 – INVESTMENT IN ALTIRA

The Company entered into its first Membership Interest Purchase Agreement (the “Purchase Agreement”) on May 13, 2020 with a member (the “First Seller”) of Altira Capital & Consulting, LLC (“Altira”). Pursuant to the Purchase Agreement, on May 13, 2020, the First Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 that was payable in four equal monthly installments of $250,000 each; 2) $3,000,000 payable on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made to the First Seller, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the 10 days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

The Company has accounted for the purchase of the 33.333% membership interest in Altira as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 33.333% membership interest in Altira indicates that the Company is able to exercise significant influence over Altira, and the Company’s membership interest is considered to be “more than minor” in accordance with the guidance. The cost of the investment was determined to be $4,000,000 pursuant to the terms of the Purchase Agreement. The contingent consideration, as described within the Purchase Agreement, in the amount of $6,000,000, will be recognized when the payments are considered probable.

For the fiscal year ended July 31, 2020, the Company determined that the investment in Altira was fully impaired and recorded an impairment charge of $4,000,000, which was the total amount of the Company’s investment recognized for the Purchase Agreement as of July 31, 2020.

On December 7, 2020, the Company purchased an additional 33.333% of membership interests in Altira, pursuant to the Membership Interest Purchase Agreement (the “Second Altira Agreement”) between the Company and another Altira member, (the “Second Seller”). With this transaction, the Company now owns a right to an aggregate 66.666% of the membership interests in Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Second Seller sold his economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive an additional 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the Membership Interest consists of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 payable on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.

Certain of the post-closing payments may be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the 10-day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

The purchase of the additional membership interests was accounted for as an asset acquisition, as Altira is not considered a business in accordance with the guidance in ASC 805, Business Combinations. The membership interests acquired do not consist of inputs, processes, and are not generating outputs, as required in ASC 805 to qualify as a business, and is therefore accounted for as an asset acquisition. Although this transaction is considered an asset acquisition, there are no assets or liabilities to be recorded as of the acquisition date as Altira does not have any business operations. The cost of the investment was determined to be $7,000,000 pursuant to the terms of the Second Altira Agreement.

For the nine months ended April 30, 2021, the Company determined that the additional purchase of the membership interests in Altira was fully impaired and recorded an impairment charge of $7,000,000, which was the total amount of the Company’s investment recognized for the Second Altira Agreement as of April 30, 2021.

During the nine months ended April 30, 2021, the Company issued 129,620 shares of Class B Common Stock totaling $3,500,000 to the First Seller for the Purchase Agreement.

Additionally, the Company issued 101,844 shares of Class B Common Stock totaling $2,750,000 to the Second Seller, and cash payments totaling $1,250,000 during the nine months ended April 30, 2021. The remaining payment due to the Second Seller, which is the contingent consideration as described within the Second Altira Agreement, of $3,000,000 is recorded as a current liability. The contingent consideration will be recognized when the payments are considered probable.

The assets and operations of Altira are not significant.

XML

Investment in RP Finance, LLC

9 Months Ended

Apr. 30, 2021

Investment In RP Finance LLC [Abstract]

INVESTMENT IN RP FINANCE, LLC

NOTE 5 – INVESTMENT IN RP FINANCE, LLC

On February 3, 2020, Rafael Pharmaceuticals entered into a Line of Credit Loan Agreement (“Line of Credit Agreement”) with RP Finance which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs.

The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals.

Under the Line of Credit Agreement, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earlier of February 3, 2025, upon a change of control of Rafael Pharmaceuticals or a sale of Rafael Pharmaceuticals or its assets. Rafael Pharmaceuticals can draw on the facility on 60 days’ notice. The funds borrowed under the Line of Credit Agreement must be repaid out of certain proceeds from equity sales by Rafael Pharmaceuticals.

In connection with entering into the Line of Credit Agreement, Rafael Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Rafael Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the Line of Credit Agreement.

RP Finance has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. Therefore, the Company will use the equity method of accounting to record the Company’s investment in RP Finance. The Company has recognized approximately $96 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance for the three months ended April 30, 2021 and 2020, respectively, and $288 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance for the nine months ended April 30, 2021 and 2020, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 11).

In August 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount of $5 million, paid in parts in August and September 2020. In November 2020, Rafael Pharmaceuticals called for a second $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount of $5 million. For the nine months ended April 30, 2021, the Company has funded a total of $3.75 million in accordance with its 37.5% ownership interest in RP Finance.

XML

Investment in LipoMedix Pharmaceuticals Ltd.

9 Months Ended

Apr. 30, 2021

Business Combinations [Abstract]

INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

NOTE 6 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

As of April 30, 2021, the Company held 68% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

In November 2019, the Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In January 2020, the Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In March 2020, the Company provided bridge financing in the principal amount of $75,000 to LipoMedix with a maturity date of April 20, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In May 2020, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 4,000,000 ordinary shares of LipoMedix for an aggregate purchase price of $1,000,000. The purchase consideration consisted of the outstanding Promissory Notes between the Company and LipoMedix dated November 13, 2019, January 21, 2020 and March 27, 2020 in the total principal amount of $300,000 plus accrued interest, for an aggregate amount of $306,737, and $693,263 of cash, thereby increasing the Company’s ownership in Lipomedix from 58% to 68%.

In March 2021, the Company provided bridge financing in the principal amount of up to $400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8% per annum. As of April 30, 2021, the Company has provided $270,379 of funding to LipoMedix. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

XML

Fair Value Measurements

9 Months Ended

Apr. 30, 2021

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7 – FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

● Level 1 - quoted prices in active markets for identical assets or liabilities;

● Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

● Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of April 30, 2021 and July 31, 2020:

	April 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	9,681	$	9,681
Total	$	—	$	—	$	9,681	$	9,681

	July 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:	(in thousands)
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

At April 30, 2021 and July 31, 2020, the Company did not have any liabilities measured at fair value on a recurring basis.

The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

	Nine Months Ended
	April 30,
	2021			2020
	(unaudited, in thousands)
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain included in earnings		4,171			492
Balance, end of period	$	9,681		$	5,617

Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. In October 2020, the Company received a $2 million distribution of the Company’s investments in Hedge Funds.

The Company holds $0.5 million in investments in securities in another entity that are not liquid, which were included in Investments - Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for under ASC 321, Investments - Equity Securities, using the measurement alternative as defined within the guidance, and the Company recorded an impairment loss of $0.7 million and $0.3 million for the nine months ended April 30, 2021 and 2020, respectively.

Fair Value of Other Financial Instruments

The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.

Cash and cash equivalents, trade accounts receivable, and accounts payable. At April 30, 2021 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1.

XML

Trade Accounts Receivable

9 Months Ended

Apr. 30, 2021

Receivables [Abstract]

TRADE ACCOUNTS RECEIVABLE

NOTE 8 – TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Trade Accounts Receivable	$	287		$	364
Accounts Receivable - Related Party		144			121
Less Allowance for Doubtful Accounts		(183	)		(218	)
Trade Accounts Receivable, net	$	248		$	267

The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $101 thousand and $11 thousand as of April 30, 2021 and July 31, 2020, respectively.

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.4 million as of both April 30, 2021 and July 31, 2020.

XML

Property and Equipment

9 Months Ended

Apr. 30, 2021

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 9 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Building and Improvements	$	47,814		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		270			256
		59,641			59,404
Less Accumulated Depreciation		(16,050	)		(14,971	)
Total	$	43,591		$	44,433

Other property and equipment consist of other equipment and miscellaneous computer hardware.

Depreciation expense pertaining to property and equipment was approximately $0.2 million and $0.5 million for the three months ended April 30, 2021 and 2020, respectively, and $1.1 million and $1.4 million for the nine months ended April 30, 2021 and 2020, respectively. 

The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey, where it occupies office space in the building owned by its subsidiary.

In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

XML

Loss per Share

9 Months Ended

Apr. 30, 2021

Earnings Per Share [Abstract]

LOSS PER SHARE

NOTE 10 – LOSS PER SHARE

Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per shares for the three and nine months ended April 30, 2021 and 2020 because all such securities are anti-dilutive for all periods presented.

The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

	Three months ended April 30,				Nine months ended April 30,
	2021		2020		2021		2020
Shares issuable upon exercise of stock options		689,210		580,874		689,210		580,874
Shares issuable upon exercise of warrants to purchase Class B common stock		26,189		—		26,189		—

The diluted loss per share computation equals basic loss per share for the three and nine months ended April 30, 2021 and 2020 because the Company had a net loss and the impact of the assumed exercise of stock options and warrants would have been anti-dilutive.

XML

Related Party Transactions

9 Months Ended

Apr. 30, 2021

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 11 – RELATED PARTY TRANSACTIONS

IDT Corporation

The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from various companies under common control to IDT. The Company recorded expense of approximately $91 thousand and $76 thousand in related party services to IDT for the three months ended April 30, 2021 and 2020, respectively, of which approximately $61 thousand and $27 thousand is included in Due to Related Parties at April 30, 2021 and 2020, respectively. The Company recorded expense of approximately $247 thousand and $232 thousand in related party services to IDT for the nine months ended April 30, 2021 and 2020, respectively, of which approximately $61 thousand and $27 thousand is included in Due to Related Parties at April 30, 2021 and 2020, respectively.

IDT leases approximately 80,000 square feet of office space plus parking at 520 Broad Street, Newark, New Jersey and approximately 3,600 square feet of office space in Jerusalem, Israel. IDT paid the Company approximately $461 thousand and $453 thousand for office rent and parking during each of the three months ended April 30, 2021 and 2020, respectively. IDT paid the Company approximately $1.38 million and $1.36 million for office rent and parking during each of the nine months ended April 30, 2021 and 2020, respectively. As of April 30, 2021 and 2020, IDT owed the Company approximately $152 thousand and $0, respectively, for office rent and parking.

During the three months ended April 30, 2021, IDT exercised 43,649 warrants to purchase shares of Class B Common Stock.

Rafael Pharmaceuticals

The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas served as the former Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $120 thousand for the three months ended April 30, 2021 and 2020, respectively, and $360 thousand for the nine months ended April 30, 2021 and 2020, respectively. As of April 30, 2021 and July 31, 2020, Rafael Pharmaceuticals owed the Company $480,000 and $118,000, respectively, included in Due from Rafael Pharmaceuticals.

Levco Pharmaceuticals Ltd

On September 8, 2020, Levco Pharmaceuticals Ltd (“Levco”) entered into a research and development consulting agreement with Dr. Alberto Gabizon for a two-year period. Under the agreement, in exchange for the services provided, Levco will pay Dr. Gabizon $3,000 per month and issue to him common shares representing up to 5% of common stock outstanding. Additionally, Levco will provide a lab grant in the amount of $120,000 to support the project.

On September 8, 2020, Levco entered into a Sponsored Research Agreement with a company for a research program related to patent applications with payments totaling $120,000 plus value-added tax. The research period is over 13 months, with two additional 12-month options to extend.

Farber Partners LLC

On December 10, 2020, a controlled subsidiary of the Company, Farber, reached an agreement with Princeton University to in-license certain patents and related information related to the serine hydroxymethyltransferase (SHMT) inhibitor program developed by the laboratory of Dr. Joshua D. Rabinowitz at Princeton. Farber will pay Princeton a minimum annual royalty payment of $50 thousand, in addition to percentage royalties and a percentage of any sublicense revenue. Additionally, there are development milestone payments which Farber will pay Princeton for the first three products developed by Farber, or any sublicensees or affiliates.

Pharma Holdings

On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.

Related Party Rental Income

The Company leases space to related parties which represented approximately 62% and 43% of the Company’s total revenue for the three months ended April 30, 2021 and 2020, respectively, and 63% and 43% for the nine months ended April 30, 2021 and 2020, respectively. See Note 16 for future minimum rent payments from related parties and other tenants.

RP Finance

For the three months ended April 30, 2021 and 2020, the Company recognized approximately $96 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively. For the nine months ended April 30, 2021 and 2020, the Company recognized $288 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively (see Note 5).

Howard Jonas, Chairman of the Board and Former Chief Executive Officer

In December 2020, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. In connection with the purchases, each purchaser was granted warrants (the “Issued Warrants”) to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of $22.91 per share and expire on June 6, 2022. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

XML

Income Taxes

9 Months Ended

Apr. 30, 2021

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

At April 30, 2021, the Company has federal net operating loss (“NOL”) carryforwards from domestic operations of approximately $44 million, to offset future taxable income. The Company has state NOLs of $27 million. The Company has NOLs from foreign operations of $3 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire.

The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s balances.

XML

Business Segment Information

9 Months Ended

Apr. 30, 2021

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

NOTE 13 – BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s CEO and chief operating decision-maker.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix, Barer, Levco, Farber, and Rafael Medical Devices are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

The Pharmaceuticals segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix, Barer, Levco, Farber, and Rafael Medical Devices. To date, the Pharmaceuticals segment has not generated any revenues.

The Real Estate segment consists of the Company’s real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage and a portion of an office building in Israel.

In August 2020, the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,658,000 in cash. At July 31, 2020, the building was classified as held for sale on the consolidated balance sheet.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended April 30, 2021
Revenues	$	—		$	990		$	990
Loss from operations		(1,417	)		(2,062	)		(3,479	)
Three Months Ended April 30, 2020
Revenues	$	—		$	1,224		$	1,224
Loss from operations		(778	)		(1,187	)		(1,965	)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine Months Ended April 30, 2021
Revenues	$	—		$	3,002		$	3,002
Loss from operations		(10,593	)		(6,194	)		(16,787	)
Nine Months Ended April 30, 2020
Revenues	$	—		$	3,670		$	3,670
Loss from operations		(1,558	)		(3,855	)		(5,413	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Nine Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
April 30, 2021
Long-lived assets, net	$	42,048	$	1,543	$	43,591
Total assets		142,764		3,444		146,208
July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

XML

Commitments and Contingencies

9 Months Ended

Apr. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix’s bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds.

On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor, or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, New Jersey. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. On February 14, 2020, the Company entered into a Settlement Agreement with OSHA, as related to the citation received on July 12, 2019. As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021, which the Company accrued for and has an outstanding balance of approximately $32,000 as of April 30, 2021. As the Company accounts for contingencies when a loss is considered probable and can be reasonably estimated, the accrued balance is for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to additional loss may exist in excess of the amount accrued.

On December 31, 2019, an employee of the Company filed a complaint in connection with the incident that led to the OSHA inspection noted above for personal injuries against the Company and other parties in the New Jersey Supreme Court for an incident that took place on January 31, 2019 at 520 Broad Street, Newark, New Jersey. The Company intends to vigorously defend this matter. The loss is considered remote and no accrual has been recorded.

The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, other than noted above, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition.

XML

Equity

9 Months Ended

Apr. 30, 2021

Stockholders' Equity Note [Abstract]

EQUITY

NOTE 15 – EQUITY

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million that was convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. In August 2019, the note, including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock.

Pursuant to the Company’s 2018 Equity Incentive Plan, three of the Company’s four non-employee directors of the Company were granted 4,203 restricted shares of Class B common stock in January 2021 and 4,203 restricted shares of Class B common stock in January 2020 which fully vested on the date of the grants. The fair value of the awards on the date of the grants were approximately $286,000 and $208,000 in January 2021 and January 2020, respectively, which was included in Selling, General and Administrative Expense.

Stock Options

A summary of stock option activity for the Company is as follows: 

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	5,269
Granted		118,409			40.85		10.00		176
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(1,323	)		—
Outstanding at April 30, 2021		689,210		$	11.08		3.29	$	21,547
Exercisable at April 30, 2021		570,801		$	4.90		1.91	$	21,371

During April 2021, 118,409 options were granted to one individual, resulting in $0.7 million in stock-based compensation expense for the three months ended April 30, 2021. These options are subject to graded vesting extending through April 15, 2025.

During the nine months ended April 30, 2021, 8,750 options were exercised. At April 30, 2021, there was unrecognized compensation cost related to non-vested stock options of $2.9 million, which is expected to be recognized over the next 2.1 years.

Restricted Stock

The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service.

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		44,070			21.92
Vested		(69,347	)		10.76
Cancelled / Forfeited		(2,099	)		13.54
Non-vested shares at April 30, 2021		95,728		$	15.28

At April 30, 2021, there was $1.6 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 2.4 years.

Share Purchase Agreement

On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the “SPA”) for the sale of 567,437 shares of the Company’s Class B common stock at a price per share of $22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020, the trading day immediately preceding the date of the SPA) for an aggregate purchase price of $13 million.

Approximately $8.2 million of the proceeds received pursuant to the SPA were used by the Company to exercise an additional portion of the Warrant in order to maintain the Company’s relative position in Rafael Pharmaceuticals in light of issuances of Rafael Pharmaceuticals equity securities to third-party shareholders of Rafael Pharmaceuticals, due to warrant exercises by these shareholders. The Company is using the remaining proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

Equity-classified Warrants

In connection with the Share Purchase Agreement, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Company issued warrants to purchase 113,487 shares of Class B common stock to the purchasers. The warrants are exercisable at a per share exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022. The Company determined that these warrants are equity-classified.

During the three months ended April 30, 2021, IDT and Genie Energy, Ltd each exercised 43,649 warrants, resulting in a total of 87,298 shares of Class B common stock issued for proceeds of approximately $2 million. At April 30, 2021, the Company had outstanding warrants to purchase 26,189 shares of Class B common stock at an exercise price of $22.91 per share, all of which expire June 6, 2022.

XML

Leases

9 Months Ended

Apr. 30, 2021

Leases [Abstract]

LEASES

NOTE 16 – LEASES

The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029. Lease income included on the consolidated statements of operations and comprehensive loss was $0.8 million and $0.9 million for the three months ended April 30, 2021 and 2020, respectively, and $2.2 million and $2.6 million for the nine months ended April 30, 2021 and 2020, respectively.

The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of April 30, 2021, under non-cancellable operating leases which expire on various dates through 2028 are as follows:

Year ending July 31,	Related Parties		Other		Total
	(in thousands)
2021 (remaining)	$	516	$	179	$	695
2022		2,078		782		2,860
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	8,525	$	4,589	$	13,114

The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

XML

Subsequent Events

9 Months Ended

Apr. 30, 2021

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

On May 27, 2021, the Company granted 908,497 restricted shares of Class B common stock of the Company to the Chief Executive Officer. Additionally, in June 2021, the Company paid a $2 million sign-on bonus to the Chief Executive Officer.

On May 27, 2021, the Company filed its Shelf Registration on Form S-3, whereby the Company may sell up to $250 million of Class B common stock. This registration was declared effective on June 7, 2021.

On May 31, 2021, the Company received a $5 million distribution of the Company’s investment in Hedge Funds.

On June 1, 2021, the Company issued 48,859 shares of Class B common stock to the Altira Second Seller totaling $2.25 million to satisfy a portion of the remaining non-contingent obligation due to the Altira Second Seller.

On June 2, 2021, the Company paid $750 thousand in cash to the Altira Second Seller to satisfy the remaining non-contingent obligation due to the Altria Second Seller.

On June 3, 2021, the Company provided $1.875 million of additional funding to RP Finance.

XML

Accounting Policies, by Policy (Policies)

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020).

Operating results for the three and nine months ended April 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (the “SEC”).

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.

Liquidity

Liquidity

Management believes that its cash on hand, planned forecast, and expected ability to meet its obligations alleviates the substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of the issuance of these financial statements. The Company has no outstanding long term debt due within 12 months and has cash reserves which will enable it to meet obligations for over a year, without attempt to monetize assets via increasing building occupancy or selling assets. The Company can liquidate its investments in hedge funds to generate cash if needed, and the Company could consider alternative sources of funding if necessary.

Risks and Uncertainties - COVID-19

Risks and Uncertainties - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings.

The impacts on the Company’s and its affiliates’ operations and specifically the ongoing clinical trials of the Company’s pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

Although partially mitigated recently, there remains a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there remains a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets.

The Company has implemented a number of measures to protect the health and safety of the Company’s workforce including a voluntary work-from-home policy for the Company’s workforce who can perform their jobs from home as well as restrictions on business travel.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, the Company cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on the Company’s business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in the Company’s customers’ behavior emanating from the pandemic and how quickly the Company can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.

Investments

Investments

The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated.

Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.

Variable Interest Entities

Variable Interest Entities

In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.”

Equity Method Investments - RP Finance, LLC (“RP Finance”) (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.

Revenue Recognition

Revenue Recognition

The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation.

The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

Research and Development Costs

Research and Development Costs

Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended.

Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.

Recently Issued Accounting Standards Not Yet Adopted

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

XML

Description of Business (Tables)

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Schedule of entities majority-owned subsidiaries

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware	100	%
Broad Atlantic Associates, LLC	United States – Delaware	100	%
IDT 225 Old NB Road, LLC	United States – Delaware	100	%
IDT R.E. Holdings Ltd.	Israel	100	%
Rafael Holdings Realty, Inc.	United States – Delaware	100	%
Barer Institute, Inc.	United States – Delaware	100	%
The Barer Institute, LLC	United States – Delaware	100	%
Hillview Avenue Realty, JV	United States – Delaware	100	%
Hillview Avenue Realty, LLC	United States – Delaware	100	%
Rafael Medical Devices, LLC	United States – Delaware	100	%
Levco Pharmaceuticals Ltd.	Israel	95	%
Farber Partners, LLC	United States – Delaware	93	%
Pharma Holdings, LLC	United States – Delaware	90	%
LipoMedix Pharmaceuticals Ltd.	Israel	68	%
Altira Capital & Consulting, LLC	United States – Delaware	67	%
CS Pharma Holdings, LLC	United States – Delaware	45	%*

XML

Fair Value Measurements (Tables)

9 Months Ended

Apr. 30, 2021

Fair Value Disclosures [Abstract]

Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy

	April 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	9,681	$	9,681
Total	$	—	$	—	$	9,681	$	9,681

	July 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:	(in thousands)
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

Schedule of changes in fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs

	Nine Months Ended
	April 30,
	2021			2020
	(unaudited, in thousands)
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain included in earnings		4,171			492
Balance, end of period	$	9,681		$	5,617

XML

Trade Accounts Receivable (Tables)

9 Months Ended

Apr. 30, 2021

Receivables [Abstract]

Schedule of trade accounts receivable

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Trade Accounts Receivable	$	287		$	364
Accounts Receivable - Related Party		144			121
Less Allowance for Doubtful Accounts		(183	)		(218	)
Trade Accounts Receivable, net	$	248		$	267

XML

Property and Equipment (Tables)

9 Months Ended

Apr. 30, 2021

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	April 30, 2021			July 31, 2020
	(unaudited, in thousands)			(in thousands)
Building and Improvements	$	47,814		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		270			256
		59,641			59,404
Less Accumulated Depreciation		(16,050	)		(14,971	)
Total	$	43,591		$	44,433

XML

Loss per Share (Tables)

9 Months Ended

Apr. 30, 2021

Earnings Per Share [Abstract]

Schedule of common share equivalents, basic and dilutive loss per share

	Three months ended April 30,				Nine months ended April 30,
	2021		2020		2021		2020
Shares issuable upon exercise of stock options		689,210		580,874		689,210		580,874
Shares issuable upon exercise of warrants to purchase Class B common stock		26,189		—		26,189		—

XML

Business Segment Information (Tables)

9 Months Ended

Apr. 30, 2021

Segment Reporting [Abstract]

Schedule of operating results for the business segments

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended April 30, 2021
Revenues	$	—		$	990		$	990
Loss from operations		(1,417	)		(2,062	)		(3,479	)
Three Months Ended April 30, 2020
Revenues	$	—		$	1,224		$	1,224
Loss from operations		(778	)		(1,187	)		(1,965	)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine Months Ended April 30, 2021
Revenues	$	—		$	3,002		$	3,002
Loss from operations		(10,593	)		(6,194	)		(16,787	)
Nine Months Ended April 30, 2020
Revenues	$	—		$	3,670		$	3,670
Loss from operations		(1,558	)		(3,855	)		(5,413	)

Schedule of revenue from tenants by geographic areas

Three Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Nine Months Ended April 30, (unaudited)	2021			2020
Revenue from tenants located in Israel		7	%		6	%

Schedule of net long-lived assets and total assets by geographic areas

(unaudited, in thousands)	United States		Israel		Total
April 30, 2021
Long-lived assets, net	$	42,048	$	1,543	$	43,591
Total assets		142,764		3,444		146,208
July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

XML

Equity (Tables)

9 Months Ended

Apr. 30, 2021

Stockholders' Equity Note [Abstract]

Schedule of stock option activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	5,269
Granted		118,409			40.85		10.00		176
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(1,323	)		—
Outstanding at April 30, 2021		689,210		$	11.08		3.29	$	21,547
Exercisable at April 30, 2021		570,801		$	4.90		1.91	$	21,371

Schedule of grants of restricted shares of Class B common stock

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		44,070			21.92
Vested		(69,347	)		10.76
Cancelled / Forfeited		(2,099	)		13.54
Non-vested shares at April 30, 2021		95,728		$	15.28

XML

Leases (Tables)

9 Months Ended

Apr. 30, 2021

Leases [Abstract]

Schedule of future contractual minimum lease payments

Year ending July 31,	Related Parties		Other		Total
	(in thousands)
2021 (remaining)	$	516	$	179	$	695
2022		2,078		782		2,860
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	8,525	$	4,589	$	13,114

XML

Description of Business (Details)	9 Months Ended
	Apr. 30, 2021
Description of Business (Details) [Line Items]
Percentage owned	50.00%
Interest percentage	45.00%
Pharma Holdings, LLC [Member]
Description of Business (Details) [Line Items]
Percentage owned	90.00%

XML

Description of Business (Details) - Schedule of entities majority-owned subsidiaries	9 Months Ended
	Apr. 30, 2021
Rafael Holdings, Inc. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Broad Atlantic Associates, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
IDT 225 Old NB Road, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
IDT R.E. Holdings Ltd. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	Israel
Percentage Owned	100.00%
Rafael Holdings Realty, Inc. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Barer Institute, Inc. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
The Barer Institute, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Hillview Avenue Realty, JV [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Hillview Avenue Realty, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Rafael Medical Devices, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	100.00%
Levco Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	Israel
Percentage Owned	95.00%
Farber Partners, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	93.00%
Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	90.00%
LipoMedix Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	Israel
Percentage Owned	68.00%
Altira Capital & Consulting, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	67.00%
CS Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]
Country of Incorporation	United States - Delaware
Percentage Owned	45.00%	[1]

[1] 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

XML

Summary of Significant Accounting Policies (Details)	Apr. 30, 2021
Accounting Policies [Abstract]
Long term debt due	12 months

XML

Investment in Rafael Pharmaceuticals (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended		9 Months Ended
	Jan. 28, 2021	Jan. 31, 2019	Apr. 30, 2021
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary			50.00%
Principal amount (in Dollars)		$ 10
Rafael Pharmaceuticals [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary			90.00%
Ownership percentage in subsidiary and holds percentage of interest			50.00%
Indirect interest in assets held, percentage			45.00%
Percentage of outstanding capital stock			51.00%
Percentage of outstanding capital stock on fully diluted basis			41.00%
CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Fully diluted			10.00%
Convertible promissory note, rate of interest		3.50%
Pharma Holdings [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary			90.00%
Exercise price of warrants or rights, description			The Company currently owns 51% of the issued and outstanding equity in Rafael Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant, which is non-dilutable and provides for the Company to increase its (via Pharma Holdings and CS Pharma and inclusive of the interests held by the other owners of those entities) total ownership to 56%. Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of April 30, 2021, the Company, and the Company’s affiliates, would need to pay approximately $17 million to exercise the Warrant in full to 56%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company and the Company’s affiliates would need to pay approximately $126 million to exercise the Warrant in full (including to offset the impact of additional issuances of Rafael Pharmaceuticals equity under the Line of Credit). The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant.
Exercise of warrants purchases, description	On January 28, 2021, Pharma Holdings partially exercised the Warrant to maintain the 51% ownership percentage and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.
Howard Jonas [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Fully diluted			10.00%
Howard Jonas [Member] | Rafael Pharmaceuticals [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Fully diluted			10.00%
Series D Convertible Preferred Stock [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Exercise of warrants purchases, description			The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
Series D Convertible Preferred Stock [Member] | CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Exercise price of warrants or rights, description			Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments.
Purchase of exercise the warrant, shares (in Shares)		16.7

XML

Investment in Altira (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 07, 2020	May 13, 2020	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Jul. 31, 2020
Investment in Altira (Details) [Line Items]
Percentage of membership interest					33.333%
Cost of investments			$ 7,000,000		$ 7,000,000
Impairment charge				$ 295,000	724,000	$ 295,000
Investment in acquired description	the Company purchased an additional 33.333% of membership interests in Altira, pursuant to the Membership Interest Purchase Agreement (the “Second Altira Agreement”) between the Company and another Altira member, (the “Second Seller”). With this transaction, the Company now owns a right to an aggregate 66.666% of the membership interests in Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Second Seller sold his economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive an additional 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the Membership Interest consists of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 payable on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.
Investments			7,000,000		7,000,000
Cash payment			6,250,000		6,250,000
Current liability			4,909,000		4,909,000		$ 5,727,000
Second Altira Agreement [Member]
Investment in Altira (Details) [Line Items]
Current liability			3,000,000		$ 3,000,000
Altira [Member]
Investment in Altira (Details) [Line Items]
Percentage of membership interest					33.333%
Cost of investments			4,000,000		$ 4,000,000
Contingent consideration			6,000,000		6,000,000
Impairment charge							$ 4,000,000
Purchase Agreement [Member]
Investment in Altira (Details) [Line Items]
Purchase agreement, description		the First Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 that was payable in four equal monthly installments of $250,000 each; 2) $3,000,000 payable on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made to the First Seller, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the 10 days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.
Class B Common Stock [Member]
Investment in Altira (Details) [Line Items]
Cash payment			$ 2,000		$ 2,000
Class B Common Stock [Member] | Second Altira Agreement [Member]
Investment in Altira (Details) [Line Items]
Issuance of shares (in Shares)					101,844
Issuance of value					$ 2,750,000
Cash payment					$ 1,250,000
Class B Common Stock [Member] | Purchase Agreement [Member]
Investment in Altira (Details) [Line Items]
Issuance of shares (in Shares)					129,620
Issuance of value					$ 3,500,000

XML

Investment in RP Finance, LLC (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 03, 2020	Aug. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Nov. 30, 2020
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds							$ 5,000,000
Income from interest			$ 96,000	$ 53,000	$ 288,000	$ 53,000
Percentage of ownership interest			37.50%		37.50%	9.00%
Line of credit facility, description		In August 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount of $5 million, paid in parts in August and September 2020.
Capital fund invested			$ 3,750,000		$ 3,750,000
Rafael Pharmaceuticals [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds							$ 5,000,000
Percentage of issued and outstanding shares			12.00%		12.00%
Percentage of ownership interest					37.50%
Line of Credit Agreement [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds	$ 50,000,000
Description line of credit facility	The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals.

XML

Investment in LipoMedix Pharmaceuticals Ltd. (Details) - USD ($)			1 Months Ended						9 Months Ended
	Mar. 27, 2020	Jan. 21, 2020	Mar. 31, 2021	May 31, 2020	Mar. 31, 2020	Jan. 31, 2020	Nov. 30, 2019	Nov. 15, 2018	Apr. 30, 2021	Nov. 13, 2019
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Issued and outstanding ordinary shares, percentage									68.00%
Bridge finance					$ 75,000	$ 125,000	$ 100,000
Maturity date					Apr. 20, 2020	May 03, 2020	May 03, 2020
Ordinary shares (in Shares)				4,000,000
Purchase price				$ 1,000,000
Total principal amount										$ 300,000
Interest, for an aggregate amount	$ 693,263	$ 306,737
Interest rate								6.00%
LipoMedix [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Principal amount			$ 400,000
Description of maturity date			September 1, 2021
Interest rate			8.00%
Fund amount									$ 270,379
Minimum [Member] | LipoMedix [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Ownership percentage				58.00%
Maximum [Member] | LipoMedix [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Ownership percentage				68.00%

XML

Fair Value Measurements (Details) - USD ($) $ in Millions	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Investment hedge funds			$ 2.0
Investments in securities	$ 0.5
Impairment loss	$ 0.7	$ 0.3

XML

Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds	$ 9,681	$ 7,510
Total	9,681	7,510
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds
Total
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds
Total
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds	9,681	7,510
Total	$ 9,681	$ 7,510

XML

Fair Value Measurements (Details) - Schedule of changes in fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of period	$ 7,510	$ 5,125
Liquidation of Hedge Fund Investments	(2,000)
Total gain included in earnings	4,171	492
Balance, end of period	$ 9,681	$ 5,617

XML

Trade Accounts Receivable (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Trade Accounts Receivable (Details) [Line Items]
Prepaid expenses and other current assets	$ 625	$ 273
Other assets	1,400	1,400
Current Portion of Deferred Rental Income [Member]
Trade Accounts Receivable (Details) [Line Items]
Prepaid expenses and other current assets	$ 101	$ 11

XML

Trade Accounts Receivable (Details) - Schedule of trade accounts receivable - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Schedule of trade accounts receivable [Abstract]
Trade Accounts Receivable	$ 287	$ 364
Accounts Receivable - Related Party	144	121
Less Allowance for Doubtful Accounts	(183)	(218)
Trade Accounts Receivable, net	$ 248	$ 267

XML

Property and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Property, Plant and Equipment [Member]
Property and Equipment (Details) [Line Items]
Depreciation expense	$ 0.2	$ 0.5	$ 1.1	$ 1.4

XML

Property and Equipment (Details) - Schedule of property and equipment - Property and Equipment [Member] - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Property, Plant and Equipment [Line Items]
Building and Improvements	$ 47,814	$ 47,591
Land	10,412	10,412
Furniture and Fixtures	1,145	1,145
Other	270	256
Property and equipment, gross	59,641	59,404
Less Accumulated Depreciation	(16,050)	(14,971)
Total	$ 43,591	$ 44,433

XML

Loss per Share (Details) - Schedule of common share equivalents, basic and dilutive loss per share - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Schedule of common share equivalents, basic and dilutive loss per share [Abstract]
Shares issuable upon exercise of stock options	689,210	580,874	689,210	580,874
Shares issuable upon exercise of warrants to purchase Class B common stock	26,189		26,189

XML

Related Party Transactions (Details)			1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 10, 2020 USD ($)	Sep. 08, 2020 USD ($)	Jan. 28, 2021	Apr. 30, 2021 USD ($) m² $ / shares	Apr. 30, 2020 USD ($) m²	Apr. 30, 2021 USD ($) m² $ / shares shares	Apr. 30, 2020 USD ($) m²	Jul. 31, 2020 USD ($)
Related Party Transactions (Details) [Line Items]
Related party expenses				$ 91,000	$ 76,000	$ 247,000	$ 232,000
Due to related parties				61,000	27,000	61,000	27,000
Due to related parties				$ 60,000		$ 60,000
Area of land (in Square Meters) | m²				3,600		3,600
Rent and parking expenses				$ 461,000	453,000	$ 1,380,000	1,360,000
Owed amount				152,000	0	152,000	0
Billed amount						360,000
Due from owed amount				$ 480,000		$ 480,000		$ 118,000
Services charges		$ 3,000
Percentage of shares outstanding		5.00%
Payments to grant amount		$ 120,000
Related party transaction, description		The research period is over 13 months, with two additional 12-month options to extend.				The Company leases space to related parties which represented approximately 62% and 43% of the Company’s total revenue for the three months ended April 30, 2021 and 2020, respectively, and 63% and 43% for the nine months ended April 30, 2021 and 2020, respectively. See Note 16 for future minimum rent payments from related parties and other tenants.
Royalty payment	$ 50,000
Description of pharma holdings			On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.
Ownership percentage, description						the Company recognized approximately $96 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively. For the nine months ended April 30, 2021 and 2020, the Company recognized $288 thousand and $53 thousand in income from its ownership interests of 37.5% in RP Finance, respectively (see Note 5).
Warrants percentage						20.00%
Warrants exercise price per share (in Dollars per share) | $ / shares				$ 22.91		$ 22.91
Securities Purchase Agreement [Member]
Related Party Transactions (Details) [Line Items]
Shares purchased (in Shares) | shares						218,245
Common stock for consideration						$ 5,000,000
Levco Pharmaceuticals Ltd [Member]
Related Party Transactions (Details) [Line Items]
Payments to grant amount		$ 120,000
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Details) [Line Items]
Billed amount				$ 120,000
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Details) [Line Items]
Due to related parties				$ 61,000	$ 27,000	$ 61,000	$ 27,000
Area of land (in Square Meters) | m²					80,000		80,000
Purchased shares (in Shares) | shares						43,649

XML

Income Taxes (Details) $ in Millions	9 Months Ended
	Apr. 30, 2021 USD ($)
Income Tax Disclosure [Abstract]
Carryforwards of domestic operations	$ 44
State of operations	27
Foreign of operations	$ 3
Taxable income	80.00%

XML

Business Segment Information (Details)	1 Months Ended	9 Months Ended
	Aug. 31, 2020	Apr. 30, 2021
Segment Reporting [Abstract]
Number of operating segments		2
Sale of building, description	the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,658,000 in cash.

XML

Business Segment Information (Details) - Schedule of operating results for the business segments - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Segment Reporting Information [Line Items]
Revenues	$ 990	$ 1,224	$ 3,002	$ 3,670
Loss from operations	(3,479)	(1,965)	(16,787)	(5,413)
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenues
Loss from operations	(1,417)	(778)	(10,593)	(1,558)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	990	1,224	3,002	3,670
Loss from operations	$ (2,062)	$ (1,187)	$ (6,194)	$ (3,855)

XML

Business Segment Information (Details) - Schedule of revenue from tenants by geographic areas	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	7.00%	6.00%	7.00%	6.00%

XML

Business Segment Information (Details) - Schedule of net long-lived assets and total assets by geographic areas - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Segment Reporting Information [Line Items]
Long-lived assets, net	$ 43,591	$ 44,433
Total assets	146,208	136,347
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	42,048	42,840
Total assets	142,764	132,286
Israel [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	1,543	1,593
Total assets	$ 3,444	$ 4,061

XML

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 17, 2018	Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Payment of consulting fees	$ 377,000
Settlement agreement, description		As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021, which the Company accrued for and has an outstanding balance of approximately $32,000 as of April 30, 2021.
Legal fees		$ 32,000

XML

Equity (Details)		1 Months Ended		3 Months Ended	6 Months Ended		9 Months Ended
	Dec. 07, 2020 USD ($) $ / shares shares	Aug. 31, 2019 USD ($)	Nov. 15, 2018 USD ($) $ / shares	Apr. 30, 2021 USD ($) $ / shares shares	Jan. 31, 2021 USD ($) shares	Jan. 31, 2020 USD ($) shares	Apr. 30, 2021 USD ($) $ / shares shares	Apr. 30, 2020 USD ($)
Equity (Details) [Line Items]
Note term			3 years
Interest rate			6.00%
Options were granted				118,409
Stock-based compensation expense | $				$ 700,000			$ 1,023,000	$ 546,000
Number of options exercised							8,750
Amount of aggregate purchase price | $	$ 13,000,000
Proceeds from issuance of common stock | $							$ 13,000,000
Exercise price | $ / shares				$ 22.91			$ 22.91
Warrant [Member]
Equity (Details) [Line Items]
Purchase of warrants granted, percentage							(20.00%)
Warrants to purchase				113,487			113,487
Warrants exercisable, description							The warrants are exercisable at a per share exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022.
Warrants exercised				87,298
Warrants outstanding				26,189			26,189
Exercise price | $ / shares				$ 22.91			$ 22.91
2018 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Restricted shares granted					4,203	4,203
Fair value of grants | $					$ 286,000	$ 208,000
IDT [Member] | Warrant [Member]
Equity (Details) [Line Items]
Warrants exercised				43,649
Genie Energy, Ltd [Member] | Warrant [Member]
Equity (Details) [Line Items]
Warrants exercised				43,649
Stock Options [Member]
Equity (Details) [Line Items]
Number of options exercised							8,750
Total unrecognized compensation cost | $				$ 2,900,000			$ 2,900,000
Unrecognized compensation cost over next period							2 years 36 days
Restricted Stock [Member]
Equity (Details) [Line Items]
Total unrecognized compensation cost | $				1,600,000			$ 1,600,000
Unrecognized compensation cost over next period							2 years 146 days
Securities Purchase Agreement [Member]
Equity (Details) [Line Items]
Proceeds from issuance of warrants | $							$ 8,200,000
Aggregate shares of common stock							218,245
Class B Common Stock [Member]
Equity (Details) [Line Items]
Convertible note | $		$ 667,000	$ 15,000,000
Conversion of common stock price per share | $ / shares			$ 8.47
Convertible into shares of common stock		1,849,749
Cash consideration | $							$ 5,000,000
Proceeds from issuance of common stock | $				$ 2,000,000
Class B Common Stock [Member] | Securities Purchase Agreement [Member]
Equity (Details) [Line Items]
Sale of stock issued	567,437
Sale of stock price per share | $ / shares	$ 22.91

XML

Equity (Details) - Schedule of stock option activity - Stock Options [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2021 USD ($) $ / shares shares
Equity (Details) - Schedule of stock option activity [Line Items]
Number of Options, Outstanding, Beginning balance | shares	580,874
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 4.90
Weighted Average Remaining Contractual Term (in years), Beginning balance	2 years 237 days
Aggregate Intrinsic Value, Beginning balance | $	$ 5,269
Number of Options, Granted | shares	118,409
Weighted Average Exercise Price, Granted | $ / shares	$ 40.85
Weighted Average Remaining Contractual Term (in years), Granted	10 years
Aggregate Intrinsic Value, Granted | $	$ 176
Number of Options, Exercised | shares	(8,750)
Weighted Average Exercise Price, Exercised | $ / shares	$ 4.90
Number of Options, Cancelled / Forfeited | shares	(1,323)
Weighted Average Exercise Price, Cancelled / Forfeited | $ / shares
Number of Options, Outstanding, Ending balance | shares	689,210
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares	$ 11.08
Weighted Average Remaining Contractual Term (in years), Ending balance	3 years 105 days
Aggregate Intrinsic Value, Ending balance | $	$ 21,547
Number of Options, Exercisable | shares	570,801
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.90
Weighted Average Remaining Contractual Term (in years) Exercisable	1 year 332 days
Aggregate Intrinsic Value, Outstanding, Exercisable | $	$ 21,371

XML

Equity (Details) - Schedule of grants of restricted shares of Class B common stock	9 Months Ended
	Apr. 30, 2021 $ / shares shares
Schedule of grants of restricted shares of Class B common stock [Abstract]
Number of Non-vested Shares, Beginning Balance | shares	123,104
Weighted Average Grant Date Fair Value, Beginning balance | $ / shares	$ 10.80
Number of Non-vested Shares, Granted | shares	44,070
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 21.92
Number of Non-vested Shares, Vested | shares	(69,347)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 10.76
Number of Non-vested Shares, Cancelled / Forfeited | shares	(2,099)
Weighted Average Grant Date Fair Value, Cancelled / Forfeited | $ / shares	$ 13.54
Number of Non-vested Shares, Ending Balance | shares	95,728
Weighted Average Grant Date Fair Value, Ending balance | $ / shares	$ 15.28

XML

Leases (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Disclosure Text Block [Abstract]
Net operating leases with initial term expiration dates			The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.
Other income	$ 0.8	$ 0.9	$ 2.2	$ 2.6
Related party leases expire, description			The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.
Annual rent			$ 2.0
Related parties terminate leases, description			The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

XML

Leases (Details) - Schedule of future contractual minimum lease payments $ in Thousands	Jul. 31, 2020 USD ($)
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	$ 695
2022	2,860
2023	2,709
2024	2,693
2025	2,209
Thereafter	1,948
Total Minimum Future Rental Income	13,114
Related Parties [Member]
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	516
2022	2,078
2023	2,117
2024	2,155
2025	1,659
Thereafter
Total Minimum Future Rental Income	8,525
Other [Member]
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	179
2022	782
2023	592
2024	538
2025	550
Thereafter	1,948
Total Minimum Future Rental Income	$ 4,589

XML

Subsequent Events (Details) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended	9 Months Ended
	Jun. 03, 2021	Jun. 30, 2021	Jun. 01, 2021	May 31, 2021	May 27, 2021	Apr. 30, 2021	Apr. 30, 2021	Jun. 02, 2021
Subsequent Events (Details) [Line Items]
Share issuance value						$ 6,250	$ 6,250
Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Distribution in Hedge Funds				$ 5,000
Altira Second Seller [Member] | Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Share issuance value			$ 2,250
Cash								$ 750
RP Finance [Member]
Subsequent Events (Details) [Line Items]
Additional funding	$ 1,875
Chief Executive Officer [Member] | Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Bonus paid		$ 2,000
Class B common stock [Member]
Subsequent Events (Details) [Line Items]
Shares issued (in Shares)						231,464	231,464
Share issuance value						$ 2	$ 2
Class B common stock [Member] | Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Restricted shares granted (in Shares)					908,497
Sale of stock value					$ 250,000
Class B common stock [Member] | Altira Second Seller [Member] | Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Shares issued (in Shares)			48,859